

This is a repository copy of *The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/114678/>

Version: Published Version

Article:

Brabyn, Sally orcid.org/0000-0001-5381-003X, Araya, Ricardo, Barkham, Michael et al. (16 more authors) (2016) The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. *Health technology assessment*. pp. 1-92. ISSN 2046-4924

<https://doi.org/10.3310/hta20890>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial

Sally Brabyn, Ricardo Araya, Michael Barkham, Peter Bower, Cindy Cooper, Ana Duarte, David Kessler, Sarah Knowles, Karina Lovell, Elizabeth Littlewood, Richard Mattock, Stephen Palmer, Jodi Pervin, David Richards, Debbie Tallon, David White, Simon Walker, Gillian Worthy and Simon Gilbody on behalf of the REEACT Team



**National Institute for
Health Research**

The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial

Sally Brabyn,¹ Ricardo Araya,² Michael Barkham,³
Peter Bower,⁴ Cindy Cooper,⁵ Ana Duarte,⁶
David Kessler,⁷ Sarah Knowles,⁴ Karina Lovell,⁸
Elizabeth Littlewood,¹ Richard Mattock,^{1,6}
Stephen Palmer,⁶ Jodi Pervin,¹ David Richards,⁹
Debbie Tallon,¹⁰ David White,¹¹ Simon Walker,⁶
Gillian Worthy¹² and Simon Gilbody^{1*} on behalf of
the REEACT Team

¹Department of Health Sciences, University of York, York, UK

²Department of Population Health, Centre of Global Mental Health, London
School of Hygiene and Tropical Medicine, London, UK

³Centre for Psychological Services Research, University of Sheffield, Sheffield, UK

⁴Centre for Primary Care, University of Manchester, Manchester, UK

⁵School of Health and Related Research, University of Sheffield, Sheffield, UK

⁶Centre for Health Economics, University of York, York, UK

⁷Academic Unit of Primary Health Care, University of Bristol, Bristol, UK

⁸School of Nursing, Midwifery and Social Work, University of Manchester,
Manchester, UK

⁹University of Exeter Medical School, University of Exeter, Exeter, UK

¹⁰School of Social and Community Medicine, University of Bristol, Bristol, UK

¹¹Clinical Trials Research Unit, University of Sheffield, Sheffield, UK

¹²York Trials Unit, University of York, York, UK

*Corresponding author

Declared competing interests of authors: David Richards reports grants from University of Exeter during the conduct of the study and is a member of the National Institute for Health Research Career Development Fellowship, Senior Research Fellowship and Transitional Research Fellowship Panel 2013 to the present.

Published November 2016

DOI: 10.3310/hta20890

This report should be referenced as follows:

Brabyn S, Araya R, Barkham M, Bower P, Cooper C, Duarte A, *et al.* The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. *Health Technol Assess* 2016;**20**(89).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.058

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nhredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/hta>

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 06/43/504. The contractual start date was in November 2013. The draft report began editorial review in July 2015 and was accepted for publication in February 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2016. This work was produced by Brabyn *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Health Technology Assessment Editor-in-Chief

Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk

Abstract

The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial

Sally Brabyn,¹ Ricardo Araya,² Michael Barkham,³ Peter Bower,⁴ Cindy Cooper,⁵ Ana Duarte,⁶ David Kessler,⁷ Sarah Knowles,⁴ Karina Lovell,⁸ Elizabeth Littlewood,¹ Richard Mattock,^{1,6} Stephen Palmer,⁶ Jodi Pervin,¹ David Richards,⁹ Debbie Tallon,¹⁰ David White,¹¹ Simon Walker,⁶ Gillian Worthy¹² and Simon Gilbody^{1*} on behalf of the REEACT Team

¹Department of Health Sciences, University of York, York, UK

²Department of Population Health, Centre of Global Mental Health, London School of Hygiene and Tropical Medicine, London, UK

³Centre for Psychological Services Research, University of Sheffield, Sheffield, UK

⁴Centre for Primary Care, University of Manchester, Manchester, UK

⁵School of Health and Related Research, University of Sheffield, Sheffield, UK

⁶Centre for Health Economics, University of York, York, UK

⁷Academic Unit of Primary Health Care, University of Bristol, Bristol, UK

⁸School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK

⁹University of Exeter Medical School, University of Exeter, Exeter, UK

¹⁰School of Social and Community Medicine, University of Bristol, Bristol, UK

¹¹Clinical Trials Research Unit, University of Sheffield, Sheffield, UK

¹²York Trials Unit, University of York, York, UK

*Corresponding author simon.gilbody@york.ac.uk

Background: Computerised cognitive behaviour therapy (cCBT) is an efficient form of therapy potentially improving access to psychological care. Indirect evidence suggests that the uptake and effectiveness of cCBT can be increased if facilitated by telephone, but this is not routinely offered in the NHS.

Objectives: To compare the clinical effectiveness and cost-effectiveness of telephone-facilitated free-to-use cCBT [e.g. MoodGYM (National Institute for Mental Health Research, Australian National University, Canberra, ACT, Australia)] with minimally supported cCBT.

Design: This study was a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial with a concurrent economic evaluation.

Setting: Participants were recruited from GP practices in Bristol, Manchester, Sheffield, Hull and the north-east of England.

Participants: Potential participants were eligible to participate in the trial if they were adults with depression scoring ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9).

Interventions: Participants were randomised using a computer-generated random number sequence to receive minimally supported cCBT or telephone-facilitated cCBT. Participants continued with usual general practitioner care.

Main outcome measures: The primary outcome was self-reported symptoms of depression, as assessed by the PHQ-9 at 4 months post randomisation.

Secondary outcomes: Secondary outcomes were depression at 12 months and anxiety, somatoform complaints, health utility (as assessed by the European Quality of Life-5 Dimensions questionnaire) and resource use at 4 and 12 months.

Results: Clinical effectiveness: 182 participants were randomised to minimally supported cCBT and 187 participants to telephone-facilitated cCBT. There was a difference in the severity of depression at 4 and 12 months, with lower levels in the telephone-facilitated group. The odds of no longer being depressed (defined as a PHQ-9 score of < 10) at 4 months were twice as high in the telephone-facilitated cCBT group [odds ratio (OR) 2.05, 95% confidence interval (CI) 1.23 to 3.42]. The benefit of telephone-facilitated cCBT was no longer significant at 12 months (OR 1.63, 95% CI 0.98 to 2.71). At 4 months the between-group difference in PHQ-9 scores was 1.9 (95% CI 0.5 to 3.3). At 12 months the results still favoured telephone-facilitated cCBT but were no longer statistically significant, with a difference in PHQ-9 score of 0.9 (95% CI -0.5 to 2.3). When considering the whole follow-up period, telephone-facilitated cCBT was associated with significantly lower PHQ-9 scores than minimally supported cCBT (mean difference -1.41, 95% CI -2.63 to -0.17; $p = 0.025$). There was a significant improvement in anxiety scores over the trial period (between-group difference 1.1, 95% CI 0.1 to 2.3; $p = 0.037$). In the case of somatic complaints (assessed using the Patient Health Questionnaire-15), there was a borderline statistically significant difference over the trial period (between-group difference 1.1, 95% CI 0.0 to 1.8; $p = 0.051$). There were gains in quality-adjusted life-years at reduced cost when telephone facilitation was added to MoodGYM. However, the results were subject to uncertainty.

Conclusions: The results showed short-term benefits from the addition of telephone facilitation to cCBT. The effect was small to moderate and comparable with that of other primary care psychological interventions. Telephone facilitation should be considered when offering cCBT for depression.

Limitations: Participants' depression was assessed with the PHQ-9, cCBT use was quite low and there was a slightly greater than anticipated loss to follow-up.

Future research recommendations: Improve the acceptability of cCBT and its capacity to address coexisting disorders. Large-scale pragmatic trials of cCBT with bibliotherapy and telephone-based interventions are required.

Trial registration: Current Controlled Trials ISRCTN55310481.

Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 20, No. 89. See the NIHR Journals Library website for further project information.

Contents

List of tables	xiii
List of figures	xv
List of abbreviations	xvii
Plain English summary	xix
Scientific summary	xxi
Chapter 1 Background	1
Depression	1
Psychological therapy for depression	1
Evidence for computerised cognitive behaviour therapy	1
Existing Health Technology Assessment programme-funded research into computerised cognitive behaviour therapy for depression: the results of the REEACT trial and the need for further research on the effectiveness of supported computerised cognitive behaviour therapy	2
Research objectives	3
Chapter 2 Methods	5
Trial design	5
Approval	5
Trial sites	5
Participants	5
<i>Inclusion criteria</i>	6
<i>Exclusion criteria</i>	6
Participant recruitment	6
<i>Direct referral</i>	6
<i>Participation identification from general practitioner records</i>	6
<i>Screening for eligibility</i>	7
<i>Consenting participants</i>	7
<i>Baseline assessment</i>	7
<i>Randomisation</i>	7
<i>Sample size</i>	7
Intervention	7
<i>Rationale</i>	9
<i>Materials</i>	9
<i>Procedures</i>	9
<i>Comparator intervention: minimally supported computerised cognitive behaviour therapy</i>	9
<i>Providers</i>	9
<i>Mode of delivery</i>	10
<i>Locations</i>	10
<i>When/how much</i>	10
<i>Tailoring</i>	10
<i>Adherence</i>	10
<i>Fidelity</i>	11
<i>Outcomes</i>	11

Statistical analysis methods	11
<i>Primary analysis</i>	11
<i>Secondary analyses</i>	13
<i>Adverse events</i>	13
Economic methods	13
<i>Health-related quality of life</i>	13
<i>Resource use and cost data</i>	14
Economic analysis: statistical methods	14
<i>Overview</i>	14
<i>Resource use and costs</i>	14
<i>Health-related quality of life</i>	15
Cost-effectiveness analysis	15
<i>Base-case and sensitivity analysis</i>	16
Patient and public participation	16
Chapter 3 Protocol changes	17
Protocol change 1: additional baseline questionnaires	17
Protocol change 2: baseline client report form	17
Protocol change 3: extension to the study date and sample size	17
Protocol change 4: primary care depression cohort	17
Chapter 4 Clinical effectiveness results	19
Randomisation and centre details	19
Baseline data	20
<i>Participant characteristics</i>	20
Primary outcome	25
<i>Patient Health Questionnaire-9 descriptive summaries</i>	25
<i>Primary analyses: depressed/not depressed (Patient Health Questionnaire-9) at month 4</i>	25
<i>Secondary analyses: depressed/not depressed (Patient Health Questionnaire-9) at month 12</i>	26
<i>Secondary analyses: repeated measures analysis of Patient Health Questionnaire-9 score</i>	27
Generalised Anxiety Disorder Scale-7 items	28
<i>Secondary analyses: Generalised Anxiety Disorder Scale-7 items</i>	28
Patient Health Questionnaire-15	30
European Quality of Life-5 Dimensions	33
Computerised cognitive behaviour therapy usage	35
Medication to help with depression use	35
Adverse events	35
Chapter 5 Economic evaluation results	39
Health-care resource use	39
Costs	40
Health-related quality of life	41
Cost-effectiveness analysis	41
<i>Base-case cost-effectiveness results</i>	41
Summary	43
Chapter 6 Discussion	45
Trial-based estimates of the clinical effectiveness of telephone-facilitated computer-delivered cognitive behaviour therapy	45
Summary of trial-based estimates of cost-effectiveness	46
Discussion of main findings	46

Conclusion	48
<i>Implications for health care</i>	48
<i>Recommendations for research</i>	48
Acknowledgements	49
References	51
Appendix 1 Sources and details of unit costs	55
Appendix 2 Patient information leaflet	57
Appendix 3 Regression coefficients used for cost-effectiveness analysis	63

List of tables

TABLE 1 Assessments and time points at which they were carried out	12
TABLE 2 Participant recruitment by site and allocation	19
TABLE 3 Participant characteristics: age and sex	20
TABLE 4 Ethnicity	21
TABLE 5 Education	21
TABLE 6 Employment details	22
TABLE 7 Family details	23
TABLE 8 Previous episodes of depression	24
TABLE 9 Patient Health Questionnaire-9 scores at each time point	25
TABLE 10 Primary analysis of depression at 4 months as a discrete outcome	25
TABLE 11 Sensitivity analysis	26
TABLE 12 Depression at 12 months as a discrete outcome	26
TABLE 13 Sensitivity analysis of depression at 12 months as a discrete outcome, assuming that those with missing data were still depressed	27
TABLE 14 Analysis of PHQ-9 score at each time point	28
TABLE 15 Mean differences in PHQ-9 score	28
TABLE 16 Generalised Anxiety Disorder Scale-7 items score	29
TABLE 17 Repeated measures analysis of GAD-7 scores	30
TABLE 18 Mean differences in GAD-7 score	30
TABLE 19 Secondary analyses: PHQ-15 score	31
TABLE 20 Repeated measures analysis of PHQ-15 score	32
TABLE 21 Mean differences in PHQ-15 score	32
TABLE 22 European Quality of Life-5 Dimensions mobility at each time point	33
TABLE 23 European Quality of Life-5 Dimensions self-care at each time point	33
TABLE 24 European Quality of Life-5 Dimensions usual activities at each time point	34

TABLE 25 European Quality of Life-5 Dimensions pain/discomfort at each time point	34
TABLE 26 European Quality of Life-5 Dimensions anxiety/depression at each time point	35
TABLE 27 MoodGYM usage data	36
TABLE 28 Self-reported antidepressant medication use	37
TABLE 29 Serious adverse events	37
TABLE 30 Resource use from baseline to 12 months of follow-up in available case data set	39
TABLE 31 Summary of costs	40
TABLE 32 European Quality of Life-5 Dimensions summary scores and QALY estimates (mean, standard error)	41
TABLE 33 Cost-effectiveness analysis summary table: base case	41
TABLE 34 Cost-effectiveness analysis summary table: sensitivity analysis excluding non-mental health-related hospital costs	43
TABLE 35 Sources and details of key unit costs	55
TABLE 36 Costs	63
TABLE 37 Quality-adjusted life-years	63

List of figures

FIGURE 1 Flow of recruitment to the trial	8
FIGURE 2 Cumulative recruitment graph for the REEACT-2 trial	19
FIGURE 3 The CONSORT flow diagram	20
FIGURE 4 Mean and 95% CI of PHQ-9 score at each assessment	27
FIGURE 5 Mean and 95% CI of GAD-7 scores at each assessment	29
FIGURE 6 Mean and 95% CI of PHQ-15 score at each assessment	31
FIGURE 7 MoodGYM usage session by session	37
FIGURE 8 Cost-effectiveness acceptability curves: base case	42
FIGURE 9 Cost-effectiveness acceptability curves: sensitivity analysis excluding non-mental health-related hospital costs	43

List of abbreviations

CBT	cognitive behaviour therapy	ISRCTN	International Standard Randomised Controlled Trial Number
cCBT	computerised cognitive behaviour therapy	NICE	National Institute for Health and Care Excellence
CI	confidence interval	OLS	ordinary least squares
CONSORT	Consolidated Standards of Reporting Trials	OR	odds ratio
CRF	client report form	PHQ-9	Patient Health Questionnaire-9
CSRI	Client Service Receipt Inventory	PHQ-15	Patient Health Questionnaire-15
EQ-5D	European Quality of Life-5 Dimensions	QALY	quality-adjusted life-year
GAD-7	Generalised Anxiety Disorder Scale-7 items	REEACT	Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy
GP	general practitioner	SD	standard deviation
HRQoL	health-related quality of life	TSW	telephone support worker
ICER	incremental cost-effectiveness ratio		

Plain English summary

Depression is a common mental health problem. An effective talking treatment for depression is cognitive behaviour therapy (CBT). Computerised CBT (cCBT) is a more recently developed form of CBT that is delivered with help from a computer rather than a face-to-face therapist. Previous research indicates that the effectiveness of cCBT can be increased when it is supported with guidance delivered by telephone. We conducted a fair test of a freely available cCBT program [MoodGYM (National Institute for Mental Health Research, Australian National University, Canberra, ACT, Australia)] delivered in two different ways. In the first way, cCBT was delivered with minimal support, as offered in the UK NHS at the moment. In the second, the same cCBT program was delivered, but in conjunction with weekly telephone calls providing guidance delivered according to a manual (telephone-facilitated cCBT).

A total of 369 people with depression were allocated either (1) cCBT with minimal support or (2) telephone-facilitated cCBT. People recruited to the trial completed questionnaires about symptoms of depression, and general and mental well-being, at 4 and 12 months after the study started.

The telephone facilitation of the cCBT program resulted in additional reductions in depression severity in the short term, but we were no longer able to detect this effect at 12 months. The provision of telephone facilitation therefore increases the effectiveness of cCBT. We found that this enhancement of care was achieved at an acceptable cost and is likely to be good value for money for the NHS. When people with depression are offered cCBT, they should also be offered telephone support to increase the chances of deriving benefit.

Scientific summary

Background

Depression is one of the most common reasons for consulting a general practitioner (GP) and its associated personal and economic burden is considerable. Although antidepressants remain an important treatment option, many patients and health-care professionals would like access to psychological therapy as an alternative or adjunct to drug therapy. Cognitive behaviour therapy (CBT) is the leading evidence-supported form of brief psychological therapy for people with depression, but the demand for CBT cannot be met with existing therapist resources. One promising alternative to therapist-delivered CBT that has the potential to increase access to psychological therapy is the provision of therapy via computers. The National Institute for Health and Care Excellence (NICE) guidelines recommend the provision of computerised CBT (cCBT) as an initial lower-intensity treatment for depression as part of a 'stepped care' approach in primary care. Much of the existing evidence for the short-term clinical effectiveness of cCBT for depression comes from research conducted by the developers of the cCBT programs. National Institute for Health Research-funded research [the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial] has recently shown that cCBT is no more effective than usual GP care and is not cost-effective. A possible explanation for the lack of effect is the low level of engagement with computer technology. Indirect evidence suggests that increasing the level of support that is offered beyond that which is routinely offered in NHS primary care psychological therapy services might increase uptake and, in turn, make the technology more effective. However, this has not been tested in a large-scale pragmatic trial conducted in primary care. The provision of a facilitated self-help program will increase the costs of cCBT, and the cost-effectiveness of a more intensively facilitated form of cCBT is not known. If psychological services were to begin routinely to offer cCBT with a higher level of support than is currently made available, then this should be on the basis of robust evidence of clinical effectiveness and cost-effectiveness. The REEACT-2 trial examines the potential of guided telephone facilitation to enhance the uptake and benefit of computer-delivered CBT.

Objectives

This was a fully randomised patient trial to examine the additional benefits of telephone facilitation and structured guidance alongside a free-to-use computer-delivered CBT package [MoodGYM (National Institute for Mental Health Research, Australian National University, Canberra, ACT, Australia)]. The comparator was a minimally supported mode of delivery of the same cCBT package that replicated the mode of delivery of cCBT, as offered in primary care in the NHS. The REEACT-2 study included a concurrent economic evaluation to meet the following specific aims:

- to establish the clinical effectiveness of a telephone-facilitated cCBT package compared with minimally supported cCBT over a 1-year trial follow-up period
- to establish the cost-effectiveness of a telephone-facilitated cCBT package compared with minimally supported cCBT over a 1-year trial follow-up period.

Methods

Design

This study was a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial with a concurrent economic evaluation. The design was a fully randomised comparative trial. Participants were

randomised using simple randomisation with allocation concealed. Treatment allocation and outcome measurement were not concealed.

Setting

Participants were recruited from UK-based GP practices in Bristol, Manchester, Sheffield, Hull and the north-east of England.

Participants

Potential participants were identified by (1) direct referral by a GP or health professional attached to a GP practice or (2) following a written approach by the GP after identification via GP practice database screening. Potential participants were eligible to participate in the trial if they were aged ≥ 18 years, scored ≥ 10 on a validated depression severity instrument [Patient Health Questionnaire-9 (PHQ-9)] and were not currently in receipt of cCBT or specialist psychological therapy.

Interventions

Participants were randomised to receive either minimally supported cCBT (MoodGYM alone) or telephone-facilitated cCBT. Each participant randomised to the telephone-facilitated cCBT arm was allocated a telephone support worker, who provided weekly telephone calls to (1) facilitate the use of a cCBT package (MoodGYM) and (2) engage in between-session exercises with problem formulation and adherence to CBT principles. All participants were also offered usual GP care.

Given the pragmatic design of the trial, no restrictions were imposed on the range of treatments that could be offered by a GP in either arm. The intervention programme was based on CBT and had been endorsed at the time of design of REEACT-2 by NICE in the initial treatment of depression in primary care. The cCBT program involved internet-based, interactive therapy sessions that could be accessed at the participant's home, in a central location close to the participant's home or at the GP practice, depending on patient preference and availability. All participants were given access to a free telephone helpline, in addition to which participants allocated to the telephone-facilitated cCBT arm were called on a weekly basis by a telephone support worker, who delivered structured guidance on the use of the cCBT program.

Main outcome measures

The primary outcome was depression at 4 months as indicated by a score of ≥ 10 on the PHQ-9. Secondary outcomes were depression severity at 4 and 12 months (PHQ-9) and anxiety [as assessed by the Generalised Anxiety Disorder Scale-7 items (GAD-7)], somatoform complaints (as assessed by the PHQ-15), health state utility (as assessed by the European Quality of Life-5 Dimensions questionnaire) and resource use at 4 and 12 months.

Results

Clinical effectiveness

One hundred and eighty-two participants were randomised to minimally supported cCBT and 187 participants were randomised to telephone-facilitated cCBT (MoodGYM). There was a difference in the severity of depression at 4 months and at 12 months, with lower levels of depression in the telephone-facilitated group. The odds of no longer being depressed (defined as a PHQ-9 score of < 10) at 4 months were twice as high in the facilitated cCBT group than in the minimally supported cCBT group [odds ratio (OR) 2.05, 95% confidence interval (CI) 1.23 to 3.42]. The benefit of telephone-facilitated cCBT was no longer significant at 12 months (OR 1.63, 95% CI 0.98 to 2.71). At 4 months the between-group difference in PHQ-9 scores was 1.9 (95% CI 0.5 to 3.3), with a standardised effect size (Cohen's *d*) of 0.32 ($p = 0.009$). At 12 months, there was no longer evidence of a between-group difference in PHQ-9 scores (0.9, 95% CI -0.5 to 2.3). Over the whole trial period, the between-group difference in PHQ-9 scores was 1.4 (95% CI 0.2 to 2.6).

There was a significant improvement in anxiety scores (GAD-7) when all time points were considered (between-group difference 1.1, 95% CI 0.1 to 2.3; $p=0.037$). In the case of somatic complaints there was a borderline significant difference when all time points were considered (between-group difference 1.1, 95% CI 0.0 to 1.8; $p=0.051$).

Scrutiny of computer records revealed that few participants completed all five sessions of either minimally supported or telephone-facilitated cCBT, but use was substantially higher among participants offered telephone facilitation.

Cost-effectiveness

Trial-based cost-effectiveness analyses showed gains in quality-adjusted life-years (QALYs) at a reduced cost when telephone facilitation was added to MoodGYM, suggesting that this was a dominant enhancement. In a more conservative sensitivity analysis, telephone facilitation was no longer cost saving but was likely to be cost-effective at £6933 per additional QALY gained. The addition of telephone facilitation was likely to be cost-effective at a £20,000 per QALY threshold (probability of cost-effectiveness of 0.55).

Conclusions

Our previous research (REEACT) has demonstrated that minimally supported cCBT is largely ineffective. Based on the results of REEACT-2, the provision of telephone facilitation appears to offer statistically significant benefits. Telephone facilitation of a free-to-use cCBT program (MoodGYM) resulted in reduced depression severity, and reduced the chances of being depressed in the short and medium term. Additional benefits were seen across secondary outcomes, including anxiety and somatoform complaints. The magnitude of effect was small to moderate and was comparable with that of other primary care-delivered psychological interventions. Telephone facilitation represented good value for money (i.e. was well within conventional thresholds used to determine value for money in the NHS). cCBT is one of a range of effective low-intensity psychological treatments that can be offered to patients, but only with telephone support.

Minimally supported cCBT (which is routinely offered in the NHS in many services) is likely to be ineffective. NHS services that currently offer cCBT should consider how best to support this technology, and this will require sufficient staff being available to offer guidance and facilitation by telephone. The results of the REEACT-2 study provide a template for telephone facilitation, which the NHS could adopt to deliver low-intensity psychological therapy at a higher volume.

The magnitude of benefits was modest, but was achieved using a low-cost low-intensity intervention.

Implications for health care

- In this trial for primary care patients with moderate depression, telephone-facilitated cCBT was clinically effective compared with minimally supported cCBT. Practice recommendations, such as those offered by NICE, and IAPT (Improving Access to Psychological Therapies) stepped models of care might usefully be re-examined in the light of these findings with due consideration of the level of support that should be offered alongside cCBT.
- Minimally supported cCBT (which is routinely offered in the NHS in many services) is ineffective and our research suggests that it should be offered only when there is sufficient staff in place to support this technology with guidance and facilitation by telephone. This can be offered by telephone according to structured delivery manuals, and allows support to be offered at low intensity and higher volume.
- Telephone-facilitated cCBT is likely to be cost saving or cost-effective to the NHS.

Recommendations for research

- The uptake and use of cCBT was not as high as expected. More research is needed to understand the reasons for lower uptake and more development is needed for cCBT products to evolve further, such that they are more acceptable to people with depression. This requires further research and innovation at the human–computer interface.
- People with depression commonly have coexisting anxiety and somatoform complaints. Although some benefits were observed in these symptoms, the cCBT materials did not specifically address these problems. Further research and development is needed to ensure that cCBT products are able to address coexisting common mental disorders within a single-treatment programme.
- cCBT is a form of self-help. It would be useful to know how cCBT compares with other forms of guided self-help, since computer-delivered therapy is not acceptable to a significant portion of patients. Large-scale pragmatic trials of treatments such as bibliotherapy or telephone-based psychological interventions are therefore needed.
- There is a need to examine the comparative effectiveness of cCBT and traditional face-to-face therapy in head-to-head trials.
- All effectiveness studies should be framed in primary care and conducted by researchers other than product developers.

Trial registration

This trial is registered as ISRCTN55310481.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Chapter 1 Background

Depression

Depression is the most common mental health disorder in community settings and is estimated to become the second largest cause of global disability by 2020.¹ It is one of the most common reasons for consulting with a general practitioner (GP) and its associated personal and economic burden is considerable.²

Psychological therapy for depression

Although antidepressants remain an important treatment option, many patients and health-care professionals would like access to psychological therapy as an alternative or adjunct to drug therapy.³ Cognitive behaviour therapy (CBT) has emerged as the leading evidence-supported form of brief psychological therapy for people with depression.^{4,5} However, demand for CBT cannot be met from existing therapist resources.⁶ One promising alternative to therapist-delivered CBT is the use of self-help interventions including the provision of therapy via a computer.⁷ In recent years a number of interactive computer programs have been developed that enable CBT to be delivered by a computer. The National Institute for Health and Care Excellence (NICE) guidelines for depression recommend the provision of computerised CBT (cCBT) as an initial, lower-intensity treatment for depression as part of a 'stepped care' approach in primary care.⁵ If effective, such programmes have the potential to expand the provision of psychological therapy in primary care and may represent an efficient and effective form of care for depression.⁸

For those who decide to use (or commission the provision of) cCBT there are a number of interactive internet-based products, some commercially produced and others free to use.⁷ In the first category, a number of commercial products have been marketed to bodies such as the NHS. Free-to-use products comprise a range of programs that have been developed by the public sector or by research institutes. These can be accessed at no direct purchase cost to health-care providers. An example of a free-to-use cCBT program is MoodGYM (National Institute for Mental Health Research, Australian National University, Canberra, ACT, Australia), which was developed in Australia and can be accessed by patients with depression, either directly or at the suggestion of their health-care provider.

Evidence for computerised cognitive behaviour therapy

Computerised CBT represents an alternative form of therapy delivery that has the potential to enhance access to psychological care. A number of systematic reviews have been conducted studying the effectiveness of cCBT. An overall beneficial effect of cCBT has been found within trials, although there is a high level of variability in effect size between studies. An early health technology assessment review by Kaltenthaler *et al.*,⁶ published in 2006, noted preliminary evidence of clinical effectiveness and cost-effectiveness. The authors noted the existence of internet-based free-to-use packages, such as MoodGYM, which had been evaluated in randomised trials, but also noted that a major limitation of the existing literature was that the trials had been conducted by the package developers.⁸ Since this review there have been few independent evaluations of cCBT packages and the randomised literature remains dominated by developer-led studies.

Later systematic reviews have also highlighted the potential for cCBT to be effective, but have also further demonstrated variable effect sizes and substantial between-study heterogeneity.^{9,10} One important source of between-study heterogeneity is the level of support that is made available to people who are offered treatment with cCBT. cCBT involves replacing the therapist with a computer, and requires the person with

depression to engage with a self-help computer-based technology. Research by Waller and Gilbody¹¹ has shown that people with depression often do not engage with cCBT, and only a minority actually complete all of the planned sessions of the computer package. This observation is consistent with a broader body of research into the uptake and effectiveness across the range of self-help interventions for depression, including bibliotherapy (self-treatment using written materials). Research in the area of self-help treatments for depression has demonstrated that entirely self-guided materials (with no professional support) are likely to be less effective than self-help technologies for which there is a level of guidance and professional support ('guided self-help'). Unsupported self-help treatment (including unsupported computer-delivered self-help) has been shown in systematic reviews to have minimal or relatively small effect sizes. In contrast, more intensively and professionally supported treatments have generally been found in efficacy trials to have moderate effect sizes claimed to be comparable to those achieved with face-to-face therapy. To our knowledge the comparative effectiveness of minimally supported cCBT versus more intensively supported cCBT has not been directly tested in large-scale, independently conducted, head-to-head effectiveness trials. Based on indirect estimates drawn from systematic reviews of trials of cCBT the effect is therefore potentially enhanced through the provision of professional support. The magnitude of benefit associated with supported cCBT in groups of patients is, on average, larger than that with unsupported/minimally supported cCBT [pooled effect size for professionally supported therapy, Cohen's $d = 0.61$, 95% confidence interval (CI) 0.45 to 0.77 vs. unsupported therapy, Cohen's $d = 0.25$, 95% CI 0.14 to 0.35].⁹

Existing Health Technology Assessment programme-funded research into computerised cognitive behaviour therapy for depression: the results of the REEACT trial and the need for further research on the effectiveness of supported computerised cognitive behaviour therapy

On the basis of a UK technology appraisal by Kaltenthaler *et al.*⁶ and the identified need for independent (non-developer-led) research into cCBT, the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial was commissioned in 2008, recruited in 2010–12 and reported in 2015.¹² The design of the REEACT trial was to compare the clinical effectiveness and cost-effectiveness of commercially developed cCBT (Beating the Blues; Ultrasis, London, UK) versus free-to-use cCBT (MoodGYM) versus usual GP care. The trial was pragmatic in design and recruited 691 participants in UK primary care. The level of support that was offered to both cCBT packages was designed to replicate current practice in NHS primary care in which professional facilitation is not routinely offered. In view of the findings of systematic reviews, and evidence of lower uptake of packages in entirely self-directed/unsupported therapies, the REEACT trial included technical telephone support. Participants were proactively offered technical support and weekly encouragement to use the computer packages, but we purposely did not augment psychological therapy over the telephone. Telephone support in the REEACT trial did not involve explanations of CBT and did not involve a review of homework or between-session tasks. The cCBT was therefore a form of supported self-help, but was not one that was guided by a clinician. The REEACT trial is, at the time of writing, the largest publicly funded, independently conducted primary care trial of cCBT.

The main finding of the REEACT trial was that for the primary outcome of depression severity at 4 months, there was no significant benefit when participants were offered technically supported cCBT in addition to usual GP care. This negative finding was true for both a free-to-use package (MoodGYM) and commercially produced cCBT (Beating the Blues). The most likely explanatory mechanism of lack of effect was poor uptake and use of computer packages by trial participants. For both cCBT packages (MoodGYM and Beating the Blues) the median number of actual computer therapy sessions that were completed by participants was between 1 and 2. The conclusion of the REEACT trial was that technically supported cCBT was clinically ineffective when added to usual GP care, and that this treatment should not routinely be offered in this form to patients with depression.

Preliminary findings from a concurrent qualitative evaluation in REEACT, and anecdotal evidence from recruiting researchers, indicated that participants were demotivated as a consequence of depression and struggled to engage with computer sessions despite appreciating the offer of technical support. Participants expressed an interest in computer packages, but identified a preference for guidance. We postulated on the basis of these findings and on the basis of emerging trial-based evidence summarised in systematic reviews (e.g. Andersson and Cuijpers⁹) that cCBT might show an effect but only if offered alongside a greater level of facilitation and support and designed the REEACT-2 study to run alongside, but independently of, REEACT and test this hypothesis. The REEACT-2 trial represents a follow-on trial from the REEACT trial to answer this related question, and most of the fundamental aspects of trial design (primary care setting, recruitment process and inclusion criteria) are replicated in the two trials.

Research objectives

This was a fully randomised patient trial to examine the additional benefits of telephone facilitation alongside a free-to-use computer-delivered CBT package (MoodGYM). The comparator was a minimally supported mode of delivery of the same cCBT package that replicated the mode of delivery of cCBT as offered in primary care in the NHS. The REEACT-2 study included a concurrent economic evaluation to meet the following specific aims:

- to establish the clinical effectiveness of a telephone-facilitated cCBT package compared with minimally supported cCBT over a 1-year trial follow-up period
- to establish the cost-effectiveness of a telephone-facilitated cCBT package compared with minimally supported cCBT over a 1-year trial follow-up period.

Chapter 2 Methods

Trial design

This study was as a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial. Participants were recruited from primary care through direct referral by their GP or a postal invitation from GP records. Participants were individually randomised to one of two arms:

1. minimally supported cCBT
2. telephone-facilitated cCBT.

Participants in both arms were given access to a free-to-use cCBT program (MoodGYM), an accompanying booklet, and a Freephone number for technical support, and continued with usual GP care. Participants in the telephone-facilitated cCBT arm were additionally allocated a telephone support worker (TSW) who provided a programme of weekly telephone calls. The programme is described in more detail in *Intervention*.

Participants were followed up over the course of 12 months, with data collected at 4 and 12 months post randomisation.

Approval

Ethics approval was granted by Bradford Research Ethics Committee (10/H1302/95) on 20 December 2010 and from relevant research and development committees. The trial was assigned the International Standard Randomised Controlled Trial Number (ISRCTN) ISRCTN55310481.

Trial sites

The study was conducted in four UK sites with well-established networks of practices from which to recruit. These were the Universities of York, Bristol, Sheffield and Manchester.

Participants

The study population included patients in primary care with depression or low mood as determined by a score of ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9).¹³ This cut-off point is known to detect clinical depression (major depression) in a UK primary care population with a sensitivity of 91.7% and a specificity of 78.3%.

The participants were recruited from a mix of rural and urban GP practices in and around Bristol, Avon, Somerset, Gloucestershire, Manchester, Sheffield and South Yorkshire, York, Humberside and East Yorkshire, Durham, Tyneside and Northumberland.

Inclusion criteria

Participants who met the following criteria were eligible to enter the study:

- aged ≥ 18 years
- not currently in receipt of cCBT or specialist psychological therapy
- score of ≥ 10 overall (indicating moderate, moderately severe or severe depression) and < 3 for item 9 (measuring suicidal thoughts)¹⁴ on the PHQ-9 depression severity measure.

Both incident and prevalent cases were included. In line with the pragmatic nature of this trial reflecting usual GP care, patients were eligible to participate whether or not they were in receipt of antidepressant medication, and those with comorbid physical illness or non-psychotic functional disorders were not excluded.

Exclusion criteria

We excluded potential participants who

- were actively suicidal as identified by the GP or as reported by item 9 on the PHQ-9
- had been bereaved within the last year
- had given birth within the last year
- had a diagnosis of psychotic depression
- had a primary diagnosis of alcohol or drug abuse
- were not able to read and write in English.

Participant recruitment

All recruiting researchers were given training in all aspects of the trial including trial recruitment, informed consent, adverse event reporting procedures, and risk assessment and reporting procedures. Each researcher was also given a study reference manual with full instructions on all the standard procedures. Participating GPs were provided with a GP manual with details of the trial processes, a GP information leaflet, adverse event reporting guidance, information about the interventions and contact details for the trial team.

Direct referral

Practices taking part in this study were provided with patient information packs containing a cover letter, patient information sheet, copy of the consent form and a prepaid envelope addressed to the local researcher, to give to patients with depression who were receptive to participating in the trial. The GP or representative could complete and fax a referral form and patient permission-to-contact form to the study researcher who, following a consideration period of at least 2 days, then approached the patient to discuss the study in more detail and confirm eligibility and continuing interest. The study design and approvals allowed that other health-care professionals attached to practices, such as nurses or primary care mental health workers, could refer patients to the study in the same way, but in the event participants were only referred by GPs.

Participation identification from general practitioner records

General practitioner practices were also asked to conduct a search of their records to identify patients presenting with depression or low mood, and screen for potentially eligible participants. Patient information packs supplied by the research team were sent from the GP practice inviting interested patients to return a completed permission-to-contact form to the research team. A member of the study team then made contact to confirm eligibility and discuss the study in further detail.

Screening for eligibility

After receiving permission-to-contact forms, the researcher contacted the potential participant to discuss the study, answer any questions and then confirm that the patient was still interested and eligible. To assess eligibility the potential participant was asked to confirm that he or she still met the inclusion criteria, in particular those that may not have been known to the GP, such as bereavement and drug and alcohol problems. The researcher also ensured that the participant understood what participation entailed, had access to the internet and wanted to take part in the trial. Participants were then asked whether they preferred the baseline assessment to be conducted over the telephone or at a face-to-face interview.

Consenting participants

Potential participants who preferred to have baseline data collected by telephone were asked to return the signed consent form in the prepaid envelope in the information pack. Those who preferred a face-to-face interview completed the consent process at the first meeting.

All potential participants were given a full explanation of the study and the opportunity to ask any questions or discuss concerns. Researchers emphasised that participants could withdraw consent at any point and would not have to give any explanation nor would their joining the study or leaving it at any point affect their GP care. Participants were also reminded that by consenting they agreed to their GPs being informed of their participation. Written informed consent was then taken, both participant and researcher signing and dating the consent forms and each keeping a copy.

Baseline assessment

Having consented to join the trial, participants completed a series of baseline questionnaires providing biographical, health status, health state utility and service use data. The participant was then randomly allocated according to the process outlined below (*Figure 1*).

Randomisation

Participants were randomly allocated in a ratio of 1 : 1 to one of two treatment conditions: (1) minimally supported cCBT or (2) telephone-facilitated cCBT. Both conditions included log-in details for a free-to-use cCBT program (MoodGYM), a booklet accompanying the program, usual GP care, and access to a free helpline for troubleshooting and general help with the program. Simple randomisation was performed using a computer-generated random number sequence. The REEACT-2 trial researchers telephoned a secure randomisation line at the York Trials Unit and were given the participant's allocation and log-in details for the MoodGYM program. By default, randomisation was done at the face-to-face interview and the participant informed immediately and given a copy of the MoodGYM booklet. If the interview finished after the randomisation line closed, the participant was informed the next day. The researcher then informed the trial manager who allocated TSWs to participants in the supported cCBT arm.

Sample size

The REEACT-2 trial was powered on the basis of an ability to detect a between-group difference in depression severity. We sought to recruit 350 patients with depression – 175 participants per arm. The REEACT-2 trial was designed to have sufficient power to detect a Cohen's *d* effect size of 0.30 with 80% power (one-sided 5% significance level) allowing for loss to follow-up of 20%, in line with our empirically based estimates from the REEACT trial. The final sample size for the two arms was 369 participants.

Intervention

In line with the template for intervention description and replication (TIDier)¹⁵ guidelines the intervention is described below using the prescribed checklist headings.




FIGURE 1 Flow of recruitment to the trial. HCP, health-care professional.

Rationale

This trial built on preliminary findings from the REEACT trial (ISRCTN91947481). In the REEACT trial, we found that participants were not always keen to engage with the cCBT programs, and they expressed a desire to receive a greater level of support. Participants were happy to receive this support over the telephone, but felt that this should reflect and emphasise the practical elements of CBT. One way to encourage engagement with self-help technologies is to offer complementary low-intensity support by telephone.¹⁶ The REEACT-2 study was designed to examine if a programme of structured telephone facilitation would enhance engagement with the MoodGYM program and whether or not enhanced engagement would lead to better outcomes. The telephone-facilitation programme was designed to be capable of delivery by appropriately trained and supervised individuals who are not necessarily people with a professional background in mental health. The support programme was designed to be delivered after a brief structured training programme and with reference to a treatment manual.

Materials

MoodGYM is a free-to-use, internet-based, interactive CBT program for depression, developed and copyrighted at the Australian National University Centre for Mental Health Research. The online program is accompanied by a booklet with exercises and quizzes, and consists of five interactive modules released sequentially and lasting approximately 30–45 minutes and a sixth session that is predominantly consolidation and revision. Study participants were asked to aim to complete one session each week. The program provides patients with CBT techniques to overcome patterns of unhelpful thinking using cartoon characters to represent habits of thought.¹⁷

Procedures

Experimental intervention: weekly supportive/facilitative telephone calls plus cCBT (telephone-facilitated cCBT).

Participants in the experimental group received regular (ideally weekly) telephone calls from a trained worker to offer support, guidance and encouragement.

The telephone facilitation programme comprised eight telephone calls to be completed alongside the cCBT program within the 12–14 weeks between the first contact from the TSW and the 4-month follow-up time point. The purpose of the first and longest session (30–40 minutes) was to introduce the participant to the principles of CBT and the MoodGYM program and booklet, explain the process and help the participant identify difficulties and goals, and feel confident about engaging with the intervention.

The following six sessions were between 10 and 20 minutes long and were intended to provide motivation and to help participants identify any barriers to engagement and to the achievement of their goal(s). The final session helped participants to consolidate what they had learned and discussed their next steps and, if appropriate, how they might use the program in the future. The telephone-facilitation programme was delivered according to a manual developed by Professor Karina Lovell in conjunction with the REEACT-2 trial team.

Comparator intervention: minimally supported computerised cognitive behaviour therapy

All patients in the control group were registered as users of MoodGYM and given a unique password. As with the intervention group, they were supplied with a free helpline number to ring if they had technical problems or needed advice, but they did not receive regular telephone calls. This comparator intervention replicates NHS care in most settings and represents what would happen if a patient were given the website of a cCBT package such as MoodGYM by their GP or primary care mental health worker without being offered proactive support.

Providers

The intervention was delivered by TSWs, a team of people specifically recruited to support the REEACT-2 trial and trained in the delivery of the manualised telephone facilitation intervention. The support workers

were not recruited to act as psychotherapists to the participant and were not instructed to replicate or consolidate the therapeutic content of the packages, as they were not trained or instructed to act as cognitive behaviour therapists.

The professional background was mixed and included psychology graduates and people who demonstrated good interpersonal skills who had worked as counsellors, social workers, psychiatric nurses and volunteers with mental health charities (e.g. Samaritans). The telephone facilitation programme was delivered according to a manual developed for the REEACT-2 trial. Full training in delivery of the programme, including the management of information that may be troubling or indicate risk, was given to all potential TSWs and their suitability to take on the role was assessed during the training and with recorded mock facilitation sessions with an experienced TSW.

Follow-up training meetings took place during the trial on a roughly bimonthly basis and TSWs had access at all times by telephone to a supervisor with a professional background in mental health (KL, mental health nursing; DK, primary care physician; and SG, psychiatrist). Between training meetings with KL, regular contact was maintained with the trial manager via e-mail and telephone. TSWs were provided with continuing case supervision every 2 weeks from the trial manager who managed the majority of day-to-day queries. Sessions with participants were recorded (with consent) and early sessions were monitored by a senior trial principal investigator for fidelity to the manual.

Mode of delivery

Participants were given a copy of the MoodGYM booklet at the baseline interview and the MoodGYM program was generally delivered via participants' own internet-connected computer, enabling participants to log on at their convenience. The default mode of delivery of the support programme was via the telephone. Three participants requested an alternative mode of communication (e-mail) because they felt too anxious to use the telephone.

Locations

Participants could log on to the MoodGYM application anywhere with broadband internet access. They were encouraged to make sure that they had a suitable environment for an appropriate length of time. Researchers could help participants to identify and book time at alternative locations with computer access such as public libraries or GP practices if they had no internet access at home or their home was not a suitable location for any reason.

Participants were encouraged to be at home, or somewhere comfortable and private for the telephone appointments. Whatever the location, to maintain privacy, the participant and TSW agreed a code word in the first session that the participant could use to indicate that it was not appropriate to continue with the conversation and that they would reconvene later.

When/how much

The TSWs contacted the participants at pre-arranged times to suit, as far as possible, the participant. This included some weekend and evening calls. The intervention provided eight telephone calls. The first of these was expected to last between 30 and 45 minutes, the following seven calls between 10 and 15 minutes, and the final call 20 minutes.

Tailoring

Telephone support workers worked to a manual but their conversations were not scripted. The telephone support programme could be tailored to some extent because there was some variation in the severity of participants' depression, their availability and their willingness or ability to complete a module each week.

Adherence

Adherence by participants to the computer program was measured by requesting information from the website providing MoodGYM (hosted by the developers of MoodGYM at the Australian National

University, Canberra, ACT, Australia). We obtained computer usage data on the number of times each participant logged on to the MoodGYM program and whether or not each module was 25%, 50%, 75% or 100% complete.

Telephone support workers kept records of the number and length of telephone sessions as well as detailed records of all attempts to contact the participants.

Fidelity

Fidelity to the telephone support manual was monitored in supervision discussion and from the recordings of the sessions. In keeping with the pragmatic nature of the trial there was a certain amount of variation in the delivery between TSWs and between participants. Telephone sessions were not formally scrutinised or analysed as a research activity, but the recordings have been retained for future reference.

Outcomes

Primary outcome measure

The primary outcome was depression severity and symptomatology as measured by a validated self-report measure (the PHQ-9)¹⁴ at 4 months because this is the point at which the largest between-group difference might be expected. The PHQ-9 logs the core symptoms of depression and takes the form of a questionnaire comprising nine sections.

Data were collected in one of four ways according to participant preference:

1. by telephone interview with a recruiting researcher
2. completion of a client report form (CRF) sent out by post
3. online
4. at a face-to-face interview with a recruiting researcher.

Secondary outcome measures

The secondary outcome measures comprised the PHQ-9 at 12 months, anxiety [as measured by the Generalised Anxiety Disorder Scale-7 items (GAD-7)];¹⁸ somatoform complaints [as measured by the Patient Health Questionnaire-15 (PHQ-15)];¹⁹ health state utility [as measured by the European Quality of Life-5 Dimensions (EQ-5D)];²⁰ and service use using the adapted Client Service Receipt Inventory (CSRI)²¹ and Client Satisfaction Questionnaire-8 items.²² The secondary outcome measures were recorded at 4 and 12 months. A summary of assessments and data collection time points can be found in *Table 1*.

Statistical analysis methods

Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) on a two-sided basis and using a 5% significance level.

Primary analysis

All outcomes were summarised descriptively by intervention group and at each time point using mean, median, standard deviation (SD), range and number of patients for continuous outcomes, and number of patients and percentage for discrete outcomes.

Patient Health Questionnaire-9 at 4 months

The primary outcome was the severity of depression as measured by the PHQ-9 at 4 months, a self-reported questionnaire. The primary analysis used the PHQ-9 score as a dichotomous outcome with a score of ≥ 10 meaning depressed and < 10 not depressed; a cut-off point of 10 has been shown to be sensitive for detecting clinical depression in UK primary care.²⁵ The PHQ-9 is a nine-item questionnaire that records the core symptoms of depression and gives a total score ranging from 0 to 27, with a higher score indicating

TABLE 1 Assessments and time points at which they were carried out

Assessment	Time point		
	Baseline	4 months	12 months
Eligibility and consent			
Eligibility	X		
Consent	X		
Background and follow-up			
Personal details	X		
Education	X		
Employment status	X		X
Marital status/living arrangements	X		
Previous episodes of depression	X	X	X
Current antidepressant medication use	X	X	X
Questionnaires			
PHQ-9 ¹⁴	X	X	X
Anxiety (GAD-7) ¹⁸	X	X	X
Somatoform symptoms (PHQ-15) ¹⁹	X	X	X
Health state utility (EQ-5D) ²⁰	X	X	X
Health economics/service utilisation questionnaire (adapted CSRI) ²¹	X	X	X
Client satisfaction survey (CSQ-8) ²²	X	X	X
Need for affect ²³	X		
Self-efficacy ²⁴	X		
CSQ-8, Client Satisfaction Questionnaire-8 items.			

more severe depression. It is categorised as follows: 0–4, none to minimal depression; 5–9, mild depression; 10–14, moderate depression; 15–19, moderately severe depression; and 20–27, severe depression. The cut-off point of 10 was used to categorise participants as depressed or not depressed at 4 and 12 months (PHQ-9 score of ≥ 10 depressed, PHQ-9 score of < 10 not depressed). To be included in the study, participants had to score of ≥ 10 on the PHQ-9 at baseline. The PHQ-9 score at each time point was calculated as the sum of all nine items. If one item was missing it was replaced with the mean of the other eight, but if two or more items were missing, then the whole questionnaire was treated as missing (using the same scoring method used in the REEACT trial).

The number and percentage of participants who were not depressed/depressed were reported at 4 and 12 months and treatment groups were compared using a chi-squared test. The missing responses were summarised and possible reasons explored by summarising and comparing baseline data between those with and without a missing outcome. The primary analysis compared minimally supported cCBT with telephone-facilitated cCBT using a logistic regression model adjusting for the baseline PHQ-9 score, age, sex, baseline GAD-7 score and treatment. Odds ratios (ORs) with 95% CIs are reported.

The primary analysis was on a complete case basis (only including those with a 4-month assessment). As some missing data were expected, sensitivity analyses were performed using imputation. A simple imputation on a worst-case scenario was used assuming that all participants with a missing outcome were still depressed. Anyone with a missing PHQ-9 score was assumed still to be depressed and have a score of ≥ 10 .

Secondary analyses

Patient Health Questionnaire-9 at 12 months

The secondary analysis of the primary outcome was the same as for the primary analysis but used the PHQ-9 score of $< 10/\geq 10$ (not depressed/depressed) at 12 months.

Patient Health Questionnaire-9 as a continuous outcome

The PHQ-9 score was also summarised and analysed as a continuous outcome. This is summarised for each assessment time point (baseline, 4 and 12 months) using mean, SD, median and range, and the number of missing values. Plots are presented showing the mean and 95% CI at each time point.

Means and SDs at the previous assessment were summarised and compared between those with and without the subsequent PHQ-9 score missing, using *t*-tests, to evaluate whether or not there were differences in scores between those with and without a missing assessment (i.e. whether or not those who dropped out were more depressed).

A repeated measures mixed regression model was used to analyse the change in PHQ-9 score over time. This included all randomised participants and provides reliable estimates assuming the data are missing at random. The outcome was the PHQ-9 score at 4 and 12 months and the model included the baseline score, treatment, age, sex, baseline GAD-7 score and time. The treatment \times time interaction was included to evaluate if the difference between treatments changed over time. Different covariance structures were evaluated (e.g. unstructured, compound symmetry) and the one providing the best fit was used. Residual plots were used to check model assumptions. The mean difference, 95% CI and *p*-values are presented for all terms in the model. Effect sizes (Cohen's *d*) were calculated for the between-group differences in mean PHQ-9 score at 4 and 12 months using the difference between the means and corresponding standard errors from the mixed model. The standard errors were converted to SDs using the corresponding sample size in each treatment group.

Other secondary outcomes

The GAD-7 and PHQ-15 scores were analysed as continuous outcomes using the same repeated measures mixed models, as described for PHQ-9 above.

The number of participants taking any medication to help with their depression was summarised descriptively at each time point. cCBT use was summarised descriptively.

Adverse events

Adverse event data were summarised descriptively.

Economic methods

The primary objective of the economic analysis was to assess the relative cost-effectiveness of telephone-facilitated cCBT compared with minimally supported cCBT. The economic analysis was conducted prospectively alongside the REEACT-2 trial.

Health-related quality of life

Decisions concerning resource allocation often need to be taken across specialties and disease areas. If these decisions are to be informed by a cost-effectiveness analysis, then it is crucial that the outcome measure adopted is generic (i.e. that it has meaning outside the clinical area within which it is used). The use of a single generic measure of health benefit enables diverse health-care interventions to be compared, thus enabling broader questions of efficiency to be addressed.

In this study, the main outcome for the cost-effectiveness analysis was the quality-adjusted life-year (QALY), assessed using the EQ-5D. The EQ-5D questionnaire is a standardised generic instrument for measuring health-related quality of life (HRQoL).²⁰ The EQ-5D consists of five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels of severity (no problems, moderate problems and severe problems) that generate 245 unique health states into which a patient can be classified. The EQ-5D also provides a single preference weight (also described as a utility or value) for each health state. These can be used as quality-adjustment weights to turn a profile of health states over time into QALYs. The EQ-5D has been validated in UK populations and has been used to measure HRQoL in patients with depression in primary care.²⁶

Resource use and cost data

Information relating to participants' resource utilisation was obtained via patient self-report using an adapted version of the CSRI.²⁷ The CSRI was administered at baseline and at each follow-up. Participants were asked about their use of services in the previous 6 months (including inpatient and outpatient hospital services, community-based day services, and primary and community care contacts); and whether or not they had incurred any additional costs associated with their depression (e.g. medication or drug costs, child-care costs, travel costs). Participants were also asked to record their use of any medication to help with their depression, including medication name, dose and duration taken.

Unit costs were obtained from routinely published national literature sources, namely the *British National Formulary*,²⁸ the Personal Social Services Research Unit's *Unit Costs of Health and Social Care*²⁹ and the NHS reference costs.³⁰ All unit costs were adjusted to 2012/13 prices using the relevant price indices. *Appendix 1* provides sources and details of the unit costs.

The costs of delivering each intervention were limited to those associated with delivering telephone support, as MoodGYM is a free-to-use software package. The cost of telephone support calls was estimated based on mean duration and mean number of support calls recorded as part of the study, and assuming the support was provided by a clinical support worker (band 2). It was assumed, after consultation with our clinical advisers, that a clinical support worker or a professional in the same pay band would provide this service in the NHS, if the intervention was to be rolled out.

The unit costs estimates were then combined with the resource utilisation data to obtain a net cost per patient over the entire follow-up period for the trial. As costs were estimated over a 12-month period, no discounting was applied.

Economic analysis: statistical methods

Overview

A within-trial economic analysis was conducted to evaluate the cost-effectiveness of telephone-facilitated cCBT (MoodGYM) and minimally supported cCBT. Costs and health benefits expressed in QALYs were estimated over the 1-year follow-up. The analysis was conducted on an intention-to-treat basis from the perspective of the UK NHS and Personal Social Services. All analyses were undertaken in Stata® 12.0 (StataCorp, College Station, TX, USA).

Resource use and costs

Descriptive statistics (mean, SD, median and interquartile range) are reported for resource use and costs. The descriptive statistics for resource use presented are based on the available case data set as multiple imputation was only performed for total costs as opposed to individual resource use items. Multiple imputation by chained equations³¹ was performed for a total of 10 imputations, and costs were imputed at every follow-up time point (baseline, 4 and 12 months) for each resource use category. The independent variables specified in the imputation were baseline EQ-5D score, baseline costs, age, sex, anxiety level at baseline, depression level at baseline and depression duration at baseline. The descriptive statistics for

resource use and costs are also reported using unadjusted estimates. Differences in mean costs (and 95% CI) between the groups were subsequently adjusted for baseline costs and additional participant covariates using regression analysis (see *Cost-effectiveness analysis*).

Health-related quality of life

Health-related quality of life was assessed using responses to the EQ-5D questionnaire applied at baseline and at 4 and 12 months. Missing EQ-5D scores were imputed by multiple imputation by chained equations alongside costs at the same follow-up time points (baseline, 4 months and 12 months) and specifying the same independent variables. The EQ-5D scores were used to estimate patient-specific QALYs using the area under the curve method³² and descriptive statistics were reported. Differences in QALYs (and 95% CI) between the groups were adjusted for additional participant covariates using regression analysis (see *Cost-effectiveness analysis*).

Cost-effectiveness analysis

Incremental estimates of total costs and QALYs were obtained through regression methods, adjusting for the following baseline characteristics: age, anxiety level, baseline depression severity, depression duration and sex. The costs and QALY estimates were also adjusted for baseline costs and baseline EQ-5D scores, respectively.

Incremental QALYs were estimated using ordinary least squares (OLS) regression, as this method has been recommended for the estimation of QALYs in economic evaluation.³³ The regression model applied for the incremental analysis of costs in the base case was a generalised linear model.³⁴ This type of model was preferred to an OLS model, as cost data tend to be heavily skewed and follow a non-normal distribution, which leads to violations of the OLS assumptions. For the analysis of costs, a gamma family distribution was selected. Selection of the family distribution was based on the modified Park's test³⁵ performed on each imputed data set and complete case data set. An identity link function was selected, thus assuming an additive effect of covariates on costs.

Cost-effectiveness was assessed by comparing the incremental costs and QALYs using standard decision rules.³⁶ An intervention that generates greater mean QALYs and lower mean costs can be considered dominant and, therefore, a cost-effective use of resources when compared with the alternative. When no dominance arises (i.e. one intervention is more costly and more effective than the other), the interventions can be compared by calculating the ratio between incremental costs and QALYs to establish the incremental cost-effectiveness ratio (ICER). When the ICER between two interventions is below the cost-effectiveness threshold that represents the rate at which health-care activities in the NHS (assumed to be cost-effective) generate health at the margin, then the more costly and more effective intervention is considered cost-effective. The cost-effectiveness of the interventions was assessed by comparing ICERs against a cost-effectiveness interval ranging from £20,000 to £30,000 per QALY, in line with NICE cost-effectiveness thresholds for the UK.³⁷

Uncertainty surrounding the decision was assessed using a probabilistic sensitivity analysis and presented through cost-effectiveness acceptability curves that graphically represent the probability of an intervention being cost-effective across a range of cost-effectiveness thresholds. The analysis was performed by simulating random draws of incremental mean costs and QALYs ($n = 1000$) from a multivariate normal distribution and estimating the proportion of those draws that corresponded to a cost-effective use of resources at cost-effectiveness threshold values ranging from £0 to £60,000 per additional QALY. In order to plot the cost-effectiveness acceptability curve, the variance-covariance matrices from the costs and QALYs regressions were extracted and the corresponding Cholesky decompositions calculated to parameterise multivariate normal distributions.³⁸ This approach is commonly used to ensure that parameters taken from a regression framework are appropriately correlated and not treated as

independent when the probabilistic sensitivity analysis is performed (and cost-effectiveness acceptability curves are plotted), but it has the disadvantage of imposing normality on the sampling distribution.

Base-case and sensitivity analysis

The base-case cost-effectiveness analysis was based on a comparison of all participants receiving minimally supported cCBT ($n = 187$) with telephone-facilitated cCBT ($n = 182$), and conducted on the multiple imputed data sets. In the base-case analysis, all categories of health-care costs were included, and QALYs estimated from EQ-5D scores were considered.

A separate sensitivity analysis undertaken, which excluded all non-mental health-related hospital costs so as to assess the robustness of base-case results to alternative assumptions in terms of costs, was also considered.

Patient and public participation

Contributors with experience of depression were involved in the design of the trial and the writing of the protocol, and the chief executive of a user-led organisation was a collaborator and coapplicant. Two people with depression read the consent forms and questionnaires and commented on the experience of completing them. All research documentation was designed with patient and public input and the trial oversight committees included members with experience of mental health problems.

Chapter 3 Protocol changes

Protocol change 1: additional baseline questionnaires

Following the emergence of preliminary findings from the REEACT trial, measures to help identify possible psychosocial mechanisms that affect participants' capacity or willingness to engage with cCBT were approved and added to the baseline CRF. They were to measure:

- need for affect, a measure of the need for emotionally stimulating experiences, which may underlie a preference for more emotionally engaging material or interaction²³
- self-efficacy, a measure of the patient's confidence that they can overcome typical difficulties to completing cCBT, which may underlie differences in motivation and ability to persist with the programme.²⁴

Protocol change 2: baseline client report form

On 29 June 2011, the Research Ethics Committee approved the addition of questions about participants' current use of antidepressant medication. Following modification of the CRFs, participants were asked the following additional questions at baseline:

If you are currently taking any medication to help with your depression please give details:

(please include both prescription medicine and any you have bought yourself)

Name of medication Dose

Name of medication Dose

How long have you been taking the medicine(s)?

Protocol change 3: extension to the study date and sample size

In December 2012, the Research Ethics Committee approval was given to increase the trial sample size to 350 (175 participants per arm) to allow the detection of a smaller difference of 0.30 with 80% power at a level of significance of 0.05 (one sided) accounting for loss to follow-up of 20%.

Protocol change 4: primary care depression cohort

In general, studies of depression in primary care can follow the progress of participants for only a short time and little is known about the effectiveness of treatments in the longer term. Research Ethics Committee approval was granted on 14 November 2012 to invite participants to continue in the study for a further 9 years answering questions about their mood and their general health. This extra follow-up period is not funded as part of the REEACT-2 trial and is not reported here.

Chapter 4 Clinical effectiveness results

Randomisation and centre details

Four main UK sites were responsible for recruiting to the trial: the Universities of Manchester, Bristol, Sheffield and York. *Table 2* shows the number of participants recruited to each arm by each site.

A total of 369 participants were randomised to the two-armed comparison of minimally supported cCBT with telephone-facilitated cCBT ($n = 182$ and $n = 187$, respectively). The first participant was randomised on 24 June 2011 and the last on 25 April 2013.

The rate of recruitment is shown in *Figure 2*. The rate had to be slowed after 3 months of rapid recruitment to accommodate the TSW workload. The flow of participants through the trial can be seen in the Consolidated Standards of Reporting Trials (CONSORT) flow chart (*Figure 3*).

TABLE 2 Participant recruitment by site and allocation

Site	Recruited (n)	Trial arm	
		Minimally supported cCBT (n)	Telephone-facilitated cCBT (n)
Bristol	154	70	84
York	124	65	59
Manchester	44	16	28
Sheffield	47	31	16
Total	369	182	187




FIGURE 2 Cumulative recruitment graph for the REEACT-2 trial.




FIGURE 3 The CONSORT flow diagram.

Baseline data

Participant characteristics

Baseline demographic characteristics are summarised in *Tables 3–7*. Continuous variables are presented as mean, SD, median and range. Categorical variables (e.g. sex) are presented as number and percentage. The number analysed and the numbers of any missing values are presented.

TABLE 3 Participant characteristics: age and sex

Participant	Trail arm		
	Minimally supported cCBT (n = 182)	Telephone-facilitated cCBT (n = 187)	Total (n = 369)
Sex, n (%)			
Male	69 (37.9)	62 (33.2)	131 (35.5)
Female	113 (62.1)	125 (66.8)	238 (64.5)
Patient age (years)			
Mean (SD)	40.3 (13.7)	41.0 (13.8)	40.6 (13.8)
Median (range)	40.6 (18.5–74.3)	40.5 (18.2–77.1)	40.6 (18.2–77.1)
Missing	0	0	0

TABLE 4 Ethnicity

Ethnicity	Trial arm		Total (N = 369), n (%)
	Minimally supported cCBT (N = 182), n (%)	Telephone-facilitated cCBT (N = 187), n (%)	
White British	173 (95.1)	174 (93.0)	347 (94.0)
Chinese	1 (0.5)	0 (0.0)	1 (0.3)
Other	1 (0.5)	3 (1.6)	4 (1.1)
White Irish	2 (1.1)	0 (0.0)	2 (0.5)
Other white	2 (1.1)	3 (1.6)	5 (1.4)
Mixed – white and black Caribbean	0 (0.0)	2 (1.1)	2 (0.5)
Mixed – white and black African	0 (0.0)	1 (0.5)	1 (0.3)
Mixed – white and Asian	0 (0.0)	1 (0.5)	1 (0.3)
Other mixed	3 (1.6)	0 (0.0)	3 (0.8)
Asian or Asian British – Indian	0 (0.0)	2 (1.1)	2 (0.5)
Asian or Asian British – Pakistani	0 (0.0)	1 (0.5)	1 (0.3)

TABLE 5 Education

Highest qualification	Trial arm		Total (N = 369), n (%)
	Minimally supported cCBT (N = 182), n (%)	Telephone-facilitated cCBT (N = 187), n (%)	
Question not answered	5	1	6
GCSE/O-level	28 (15.8)	31 (16.7)	59 (16.3)
GCE A-/AS-level or Scottish Higher	23 (13.0)	28 (15.1)	51 (14.0)
NVQ/SVQ levels 1–3	22 (12.4)	24 (12.9)	46 (12.7)
GNVQ (Advanced)	1 (0.6)	6 (3.2)	7 (1.9)
BTEC Certificate	1 (0.6)	2 (1.1)	3 (0.8)
BTEC Diploma	7 (4.0)	3 (1.6)	10 (2.8)
National Certificate or Diploma (ONC/OND)	10 (5.6)	20 (10.8)	30 (8.3)
Qualified Teacher Status	4 (2.3)	3 (1.6)	7 (1.9)
Higher Education Diploma	6 (3.4)	9 (4.8)	15 (4.1)
Degree (first/ordinary)	33 (18.6)	28 (15.1)	61 (16.8)
Post-graduate certificate	6 (3.4)	5 (2.7)	11 (3.0)
Post-graduate diploma	2 (1.1)	2 (1.1)	4 (1.1)
Master's degree	10 (5.6)	8 (4.3)	18 (5.0)
PhD	1 (0.6)	2 (1.1)	3 (0.8)
Do not know/no response	17 (9.6)	10 (5.4)	27 (7.4)
Other	6 (3.4)	5 (2.7)	11 (3.0)

A-level, Advanced level; AS-level, Advanced Subsidiary level; BTEC, Business and Technology Education Council; GCE, General Certificate of Education; GCSE, General Certificate of Secondary Education; GNVQ, General National Vocational Qualification; NVQ, National Vocational Qualification; O-Level, Ordinary level; ONC, Ordinary National Certificate; OND, Ordinary National Diploma; PhD, Doctor of Philosophy; SVQ, Scottish Vocational Qualification.

TABLE 6 Employment details

Employment status	Trial arm		Total (N = 369), n (%)
	Minimally supported cCBT (N = 182), n (%)	Telephone-facilitated cCBT (N = 187), n (%)	
Baseline employment			
Employed part-time	19 (10.4)	33 (17.7)	52 (14.1)
Other	2 (1.1)	1 (0.5)	3 (0.8)
Employed full-time	76 (41.8)	71 (38.2)	147 (39.9)
Self-employed	11 (6.0)	14 (7.5)	25 (6.8)
Retired	11 (6.0)	13 (7.0)	24 (6.5)
Looking after family or home	8 (4.4)	8 (4.3)	16 (4.3)
Not employed but seeking work	15 (8.2)	9 (4.8)	24 (6.5)
Not employed but not seeking work because of ill health	16 (8.8)	20 (10.8)	36 (9.8)
Not employed but not seeking work for other reasons	1 (0.5)	2 (1.1)	3 (0.8)
Full-time student	23 (12.6)	15 (8.1)	38 (10.3)
If employed or self-employed, off sick because of depression?			
Yes	26 (22.2)	31 (24.8)	57 (23.6)
No	90 (76.9)	94 (75.2)	184 (76.0)
Missing	1 (0.9)	0 (0.0)	1 (0.4)
If unemployed, for how long?			
< 3 months	3 (7.7)	5 (10.9)	8 (9.4)
4–12 months	10 (25.6)	9 (19.6)	19 (22.4)
1–2 years	9 (23.1)	5 (10.9)	14 (16.5)
2–5 years	6 (15.4)	7 (15.2)	13 (15.3)
> 5 years	7 (17.9)	10 (21.7)	17 (20.0)
No response	4 (10.3)	10 (21.7)	14 (16.5)
Most recent job			
Question not answered	10	5	15
Foreman/supervisor	18 (10.5)	16 (8.8)	34 (9.6)
Manager	33 (19.2)	33 (18.1)	66 (18.6)
Self-employed with employees	5 (2.9)	5 (2.7)	10 (2.8)
Self-employed without employees	8 (4.7)	15 (8.2)	23 (6.5)
Other employee	103 (59.9)	109 (59.9)	212 (59.9)
Never been in paid employment	5 (2.9)	4 (2.2)	9 (2.5)

TABLE 7 Family details

Family details	Trial arm		Total (N = 369), n (%)
	Minimally supported cCBT (N = 182), n (%)	Telephone-facilitated cCBT (N = 187), n (%)	
Baseline marriage/family status			
Married	68 (37.4)	68 (36.6)	136 (37.0)
Living with a partner	21 (11.5)	36 (19.4)	57 (15.5)
Divorced/separated	24 (13.2)	31 (16.7)	55 (14.9)
Widowed	5 (2.7)	4 (2.2)	9 (2.4)
Single (never married)	63 (34.6)	45 (24.2)	108 (29.3)
Other	1 (0.5)	2 (1.1)	3 (0.8)
If married, does your spouse live with you?			
Yes	69 (88.5)	71 (88.8)	140 (88.6)
No	4 (5.1)	2 (2.5)	6 (3.8)
Missing	5 (6.4)	7 (8.8)	12 (7.6)
Do you have other people living with you?			
Question not answered	1	1	2
Yes	120 (66.3)	116 (62.4)	236 (64.3)
No	60 (33.1)	70 (37.6)	130 (35.4)
If yes, how many?			
1	44 (36.4)	48 (40.0)	92 (38.2)
2	44 (36.4)	32 (26.7)	76 (31.5)
3	18 (14.9)	27 (22.5)	45 (18.7)
4	9 (7.4)	7 (5.8)	16 (6.6)
5	3 (2.5)	1 (0.8)	4 (1.7)
6	0 (0.0)	1 (0.8)	1 (0.4)
≥ 7	2 (1.7)	1 (0.8)	3 (1.2)
Do not know/no response	1 (0.8)	3 (2.5)	4 (1.7)
How many are < 18 years?			
0	60 (50.0)	56 (47.1)	116 (48.5)
1	25 (20.8)	30 (25.2)	55 (23.0)
2	23 (19.2)	19 (16.0)	42 (17.6)
3	6 (5.0)	12 (10.1)	18 (7.5)
4	3 (2.5)	1 (0.8)	4 (1.7)
≥ 7	1 (0.8)	0 (0.0)	1 (0.4)
Do not know/no response	2 (1.7)	1 (0.8)	3 (1.3)

The two groups were well balanced at baseline for sex, age, ethnicity and education. The mean age of participants was 40.6 years (SD 13.8 years). The study population was mostly white British (94%) and 64.5% were female.

The minimally supported cCBT and telephone-facilitated cCBT groups were balanced at baseline for employment. The majority (61.5%) of participants were employed, and, of these, 23.6% were off work with depression at the time of their baseline assessment.

The two groups were balanced at baseline regarding marriage and family status.

Baseline clinical data

The two groups had an imbalance at baseline in the proportion of participants describing themselves as chronically depressed (11% minimally supported cCBT vs. 5.9% telephone-facilitated cCBT), but the numbers are very small.

As can be seen in *Table 8*, the majority of participants (70.7%) had sought help for previous episodes of depression and 84.5% of these had previously been prescribed antidepressant medication (60.4% of the trial sample), and 38.8% of participants reported taking antidepressant medication at baseline. Randomisation resulted in the groups being well balanced for all these variables.

TABLE 8 Previous episodes of depression

Episodes of depression	Trial arm		Total (N = 369), n (%)
	Minimally supported cCBT (N = 182), n (%)	Telephone-facilitated cCBT (N = 187), n (%)	
<i>Previous episodes of depression when help was sought?</i>			
Yes	127 (69.8)	134 (71.7)	261 (70.7)
No	53 (29.1)	52 (27.8)	105 (28.5)
Do not know	2 (1.1)	1 (0.5)	3 (0.8)
<i>If yes, how many episodes of treated depression?</i>			
1	36 (28.3)	46 (34.1)	82 (31.3)
2	25 (19.7)	36 (26.7)	61 (23.3)
3	20 (15.7)	9 (6.7)	29 (11.1)
4	12 (9.4)	7 (5.2)	19 (7.3)
≥ 5	20 (15.7)	29 (21.5)	49 (18.7)
Chronically depressed	14 (11.0)	8 (5.9)	22 (8.4)
<i>If yes, prescribed antidepressants for a previous episode?</i>			
Yes	109 (85.2)	114 (83.8)	223 (84.5)
No	19 (14.8)	19 (14.0)	38 (14.4)
Do not know	0 (0.0)	3 (2.2)	3 (1.1)
<i>Currently taking medication for depression?</i>			
Yes	71 (39.0)	72 (38.5)	143 (38.8)
No	111 (61.0)	115 (61.5)	226 (61.2)
Seen anyone other than your GP?	94 (74.0)	96 (71.1)	190 (72.5)
Psychiatrist	26 (14.4)	25 (13.4)	51 (13.9)
Psychologist	15 (8.3)	16 (8.6)	31 (8.5)
Counsellor	65 (35.7)	66 (35.3)	131 (35.5)
Community psychiatric nurse	10 (5.6)	18 (9.7)	28 (7.7)
Social worker	3 (1.7)	3 (1.6)	6 (1.6)
Citizens advice bureau	0	0	0
Other statutory/voluntary agency	3 (1.7)	10 (5.4)	13 (3.6)
Other	12 (6.7)	10 (5.4)	22 (6.0)
Do not know	0 (0.0)	1 (0.5)	1 (0.3)

Primary outcome

Patient Health Questionnaire-9 descriptive summaries

At the 4-month follow-up, a PHQ-9 score was missing for 27% of participants who did not return the 4-month questionnaire, 25% in the telephone-facilitated cCBT group and 30% in the minimally supported cCBT group. These numbers were slightly lower at month 12, 24% in the telephone-facilitated cCBT group and 27% in the minimally supported cCBT group, as a small number of participants completed a 12-month but not a 4-month questionnaire. Scores are summarised in *Table 9*.

Participants in the telephone-facilitated cCBT group had lower mean PHQ-9 scores at month 4 (indicating a reduction in depression) with a between-group difference of 1.9 at month 4 and 1 at month 12.

Primary analyses: depressed/not depressed (Patient Health Questionnaire-9) at month 4

Primary analysis results are shown in *Table 10*. After 4 months, 66 (50.30%) of the 128 participants in the minimally supported cCBT group and 51 (36.2%) of the 141 in the telephone-facilitated cCBT group had a PHQ-9 score of ≥ 10 .

TABLE 9 Patient Health Questionnaire-9 scores at each time point

PHQ-9	Time point					
	Baseline		Month 4		Month 12	
	Minimally supported cCBT (n = 182)	Telephone-facilitated cCBT (n = 187)	Minimally supported cCBT (n = 128)	Telephone-facilitated cCBT (n = 141)	Minimally supported cCBT (n = 132)	Telephone-facilitated cCBT (n = 142)
PHQ-9 score						
Mean (SD)	16.4 (4.1)	16.8 (3.9)	10.4 (6.4)	8.5 (6.3)	9.2 (6.2)	8.2 (6.4)
Median	16	17	10	7	9	7
Range	10–25	10–26	0–27	0–24	0–25	0–27
PHQ-9 dichotomised						
Depressed, n (%)	182 (100)	187 (100)	66 (51.6)	51 (36.2)	57 (43.2)	46 (32.4)
Not depressed, n (%)	0	0	62 (48.4)	90 (63.8)	75 (56.8)	96 (67.6)
Missing, n (%)	0	0	54 (30)	46 (25)	50 (27)	45 (24)

TABLE 10 Primary analysis of depression at 4 months as a discrete outcome

Effect	OR	95% CI	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT	2.050	1.227 to 3.424	0.0061
Male vs. female	0.957	0.559 to 1.638	0.8713
Baseline PHQ-9 score	0.882	0.819 to 0.951	0.0011
Baseline GAD-7 score	0.964	0.903 to 1.029	0.2654
Age (years)	1.012	0.994 to 1.031	0.1981

As a sensitivity analysis, an alternative scenario was also considered that assumed all participants who did not supply follow-up data remained depressed.

Both primary and sensitivity analyses of depression as a discrete outcome show a significant difference between the groups with respect to the odds of not being depressed at 4 months. For the primary analysis the OR was 2.05 (95% CI 1.23 to 3.24; $p = 0.006$), indicating that adding telephone support to cCBT doubled the odds of not being depressed. The baseline PHQ-9 score was also a significant predictor, indicating that a higher baseline score was related to a reduced chance of not being depressed. *Table 11* shows the results of the sensitivity analysis, which included all participants and assumed that those with missing data were still depressed. The conclusion regarding the addition of telephone support was the same. In this analysis, age and baseline GAD-7 score also had statistically significant relationships with the odds of not being depressed. Older participants were more likely to not be depressed at month 4, whereas those participants with higher baseline depression and anxiety were less likely not to be depressed.

The missing data were explored using univariate logistic regression models to compare baseline factors between those with and those missing a month-4 PHQ-9 score. There was no relationship between missing assessments and treatment ($p = 0.274$), baseline PHQ-9 score ($p = 0.898$), sex ($p = 0.272$) or taking current medication for depression ($p = 0.134$). However, age (OR 1.03, 95% CI 1.01 to 1.05; $p = 0.002$) and baseline GAD-7 score (OR 0.94, 95% CI 0.89 to 0.99; $p = 0.023$) were both significantly associated with the odds of missing a month-4 assessment. This indicates that older participants were more likely to have a missing assessment, and those with higher anxiety at baseline were less likely to have a missing assessment.

Secondary analyses: depressed/not depressed (Patient Health Questionnaire-9) at month 12

Tables 12 and 13 show the results of modelling the odds of being depressed or not depressed at month 12, with a graphical representation in *Figure 4*. Again the analysis was carried out with all available data and then with the assumption that participants whose data were missing remained depressed as a sensitivity analysis.

TABLE 11 Sensitivity analysis


Effect	OR	95% CI	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT	1.945	1.253 to 3.019	0.0030
Male vs. female	0.784	0.496 to 1.240	0.2977
Baseline PHQ-9 score	0.925	0.869 to 0.984	0.0137
Baseline GAD-7 score	0.938	0.887 to 0.991	0.0232
Age (years)	1.020	1.004 to 1.037	0.0132

TABLE 12 Depression at 12 months as a discrete outcome

Effect	OR	95% CI	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT	1.626	0.977 to 2.705	0.0615
Male vs. female	1.111	0.651 to 1.897	0.6996
Baseline PHQ-9 score	0.898	0.833 to 0.967	0.0046
Baseline GAD-7 score	0.965	0.904 to 1.031	0.2892
Age (years)	1.004	0.986 to 1.023	0.6764

TABLE 13 Sensitivity analysis of depression at 12 months as a discrete outcome, assuming that those with missing data were still depressed

Effect	OR	95% CI	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT	1.613	1.051 to 2.474	0.0286
Male vs. female	0.979	0.627 to 1.528	0.9249
Baseline PHQ-9 score	0.930	0.875 to 0.987	0.0177
Baseline GAD-7 score	0.941	0.891 to 0.994	0.0290
Age (years)	1.018	1.002 to 1.034	0.0263

**FIGURE 4** Mean and 95% CI of PHQ-9 score at each assessment.

These results show that telephone-facilitated cCBT was better than minimally supported cCBT for increasing the chances of no longer being depressed after 12 months, but this was not statistically significant (OR 1.63, 95% CI 0.98 to 2.71; $p = 0.06$). However, in the sensitivity analysis, assuming participants with a missing PHQ-9 score were still depressed, telephone-facilitated cCBT was significantly better (OR 1.61, 95% CI 1.05 to 2.47; $p = 0.03$).

The OR was 1.61 (95% CI 1.05 to 2.47; $p = 0.028$) for the main analysis and 1.63 (95% CI 0.98 to 2.71; $p = 0.062$) for the sensitivity analysis, indicating that adding telephone support to cCBT increased the odds of no longer being depressed by approximately 60%. The baseline PHQ-9 score was also a significant predictor, indicating that a higher baseline score was related to a reduced chance of not being depressed.

Secondary analyses: repeated measures analysis of Patient Health Questionnaire-9 score

The mixed repeated measures model is reported in *Tables 14* and *15*. These results show a statistically significant overall effect of treatment ($p = 0.025$), indicating that over both follow-up assessments the addition of telephone support to cCBT reduced the PHQ-9 score by approximately -1.41 (95% CI -2.63 to -0.17). Over both groups there was also a statistically significant reduction over time ($p = 0.025$), indicating a general decrease in score over time. The baseline PHQ-9 score was a significant predictor of follow-up PHQ-9 score ($p < 0.001$) but there was no evidence of any relationship with age, sex or baseline GAD-7 score.

TABLE 14 Analysis of PHQ-9 score at each time point

Effect	Estimate	95% CI	F-value	p-value
Baseline PHQ-9 score	0.4813	0.3025 to 0.6600	28.07	< 0.0001
Baseline GAD-7 score	0.1301	-0.02763 to 0.2878	2.64	0.1056
Age (years)	-0.0183	-0.0622 to 0.0256	0.68	0.4119
Sex	0.4899	-0.8039 to 1.7836	0.75	0.4567
Time	Overall effect		5.08	0.0250
Treatment	Overall effect		5.05	0.0253
Treatment x time interaction	Overall effect		1.94	0.1645

TABLE 15 Mean differences in PHQ-9 score

Effect	Cohen's <i>d</i> effect size	Estimate	95% CI	t-value	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT (month 4)	0.324	-1.8923	-3.2969 to -0.4877	2.65	0.0085
Telephone-facilitated cCBT vs. minimally supported cCBT (month 12)	0.155	-0.9192	-2.3341 to 0.4957	1.28	0.2020
Telephone-facilitated cCBT vs. minimally supported cCBT (over all assessments)		-1.4057	-2.6336 to -0.1748	2.25	0.0253
Month 4 vs. month 12 (over all treatments)		0.7866	0.0995 to 1.4737	2.25	0.0250

The PHQ-9 score for telephone-facilitated cCBT was significantly lower than minimally supported cCBT after 4 months (mean between-group difference -1.89, 95% CI -3.30 to -0.49; Cohen's *d* = 0.324; $p = 0.009$), but there was no evidence of any difference after 12 months.

Generalised Anxiety Disorder Scale-7 items

The GAD-7 questionnaire was measured at baseline and at 4 and 12 months.

Secondary analyses: Generalised Anxiety Disorder Scale-7 items

The GAD-7 questionnaire was administered to assess self-reported anxiety at baseline and at 4 and 12 months. The mean score decreased in both groups during both follow-up periods.


Table 16 and Figure 5 show the mean GAD-7 scores for each group for the period for the trial. The scores in each group decreased over both time periods.

Results are from a mixed model with repeated measures within participants to allow for within-participant correlation. An unstructured covariance matrix was used. The model analysed GAD-7 scores at months 4 and 12, and adjusted for age, sex, baseline PHQ-9 score, baseline GAD-7 score, time (as a categorical variable) and treatment.

Cohen's *d* effect size was calculated as an estimate of mean difference/overall SD.

TABLE 16 Generalised Anxiety Disorder Scale-7 items score

Time point	Trial arm		Total (<i>n</i> = 369)
	Minimally supported cCBT (<i>n</i> = 182)	Telephone-facilitated cCBT (<i>n</i> = 187)	
Baseline			
Mean (SD)	14.1 (4.4)	14.5 (4.4)	14.3 (4.4)
Median (range)	14.0 (4.0–21.0)	15.0 (3.0–21.0)	15.0 (3.0–21.0)
Missing	0	0	0
Month 4			
Mean (SD)	8.6 (5.4)	7.5 (6.1)	8.1 (5.8)
Median (range)	8.0 (0.0–21.0)	6.0 (0.0–21.0)	7.0 (0.0–21.0)
Missing	65	59	124
Month 12			
Mean (SD)	8.2 (5.6)	7.0 (5.7)	7.6 (5.7)
Median (range)	7.0 (0.0–21.0)	5.0 (0.0–21.0)	6.0 (0.0–21.0)
Missing	59	56	115

**FIGURE 5** Mean and 95% CI of GAD-7 scores at each assessment.

The results in *Tables 17* and *18* show a statistically significant overall effect of treatment ($p = 0.037$), indicating that over the whole follow-up period the addition of telephone support to cCBT reduced the GAD-7 score by approximately -1.18 (95% CI -2.28 to -0.07). However, when comparing the treatments separately at month 4 and month 12, there was no statistically significant difference between them at either assessment. Baseline GAD-7 and PHQ-9 scores were significant predictors of follow-up GAD-7 score.

TABLE 17 Repeated measures analysis of GAD-7 scores

Effect	Estimate	95% CI	F-value	p-value
Baseline PHQ-9 score	0.1992	0.0388 to 0.3596	5.98	0.0151
Baseline GAD-7 score	0.4338	0.2917 to 0.5759	36.12	<0.0001
Age (years)	-0.0358	-0.0750 to 0.0034	3.24	0.0730
Sex	0.5970	-0.5812 to 1.7752	0.99	0.3194
Time	Overall effect		3.34	0.0690
Treatment	Overall effect		4.42	0.0365
Treatment x time interaction	Overall effect		0.02	0.8806

TABLE 18 Mean differences in GAD-7 score

Effect	Cohen's <i>d</i> effect size	Estimate	95% CI	t-value	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT (month 4)	0.236	-1.2291	-2.4374 to 0.1425	1.85	0.0659
Telephone-facilitated cCBT vs. minimally supported cCBT (month 12)	0.166	-1.1269	-2.3122 to 0.1676	1.75	0.0819
Telephone-facilitated cCBT vs. minimally supported cCBT (over all assessments)		-1.1780	-2.2813 to -0.0747	2.10	0.0365
Month 4 vs. month 12 (over all treatments)		0.6203	-0.0487 to 1.2894	1.83	0.0690

Patient Health Questionnaire-15

The PHQ-15 was administered to assess somatoform symptoms at baseline and at 4 and 12 months, and descriptive statistics are presented in *Table 19* and *Figure 6*.

Results are from a mixed model with repeated measures within participants to allow for within-participant correlation. An unstructured covariance matrix was used. The model analysed PHQ-15 scores at months 4 and 12, and adjusted for age, sex, baseline PHQ-15 score, baseline GAD-7 score, time (as a categorical variable) and treatment.

Cohen's *d* effect size was calculated as an estimate of mean difference/overall SD.

TABLE 19 Secondary analyses: PHQ-15 score

Time point	Trial arm		Total (n = 369)
	Minimally supported cCBT (n = 182)	Telephone-facilitated cCBT (n = 187)	
Baseline			
Mean (SD)	11.5 (4.8)	11.9 (5.0)	11.7 (4.9)
Median (range)	11.0 (1.0–28.0)	11.0 (1.0–28.0)	11.0 (1.0–28.0)
Missing	0	0	0
Month 4			
Mean (SD)	8.7 (4.7)	8.8 (5.5)	8.7 (5.1)
Median (range)	8.0 (0.0–21.4)	8.0 (0.0–25.0)	8.0 (0.0–25.0)
Missing	66	59	125
Month 12			
Mean (SD)	9.0 (5.1)	8.2 (5.0)	8.6 (5.1)
Median (range)	8.0 (0.0–25.0)	7.0 (0.0–20.0)	8.0 (0.0–25.0)
Missing	60	57	117




FIGURE 6 Mean and 95% CI of PHQ-15 score at each assessment.

These results (Tables 20 and 21) show a borderline statistically significant overall effect of treatment ($p = 0.051$), indicating that over the whole follow-up period the addition of telephone support to cCBT reduced the PHQ-15 score by approximately -1.11 (95% CI -1.75 to 0.002). When comparing the treatments separately at month 4 and month 12, there was no statistically significant difference between them at month 4 but the PHQ-15 score was significantly lower with the addition of telephone facilitation at month 12 (mean difference -1.24 , 95% CI -2.27 to -0.21 ; $p = 0.018$).

Baseline PHQ-15 score was the only other significant predictor of follow-up PHQ-15 score (see Table 20).

TABLE 20 Repeated measures analysis of PHQ-15 score

Effect	Estimate	95% CI	F-value	p-value
Baseline GAD-7 score	0.0467	-0.0558 to 0.1491	0.81	0.3704
Baseline PHQ-15 score	0.5800	0.4819 to 0.6780	135.66	< 0.0001
Age (years)	0.0062	-0.0252 to 0.0375	0.15	0.6994
Sex	-0.5926	-1.5394 to 0.3542	1.52	0.2189
Time	Overall effect		1.24	0.2661
Treatment	Overall effect		3.85	0.0506
Treatment × time interaction	Overall effect		1.62	0.2050

TABLE 21 Mean differences in PHQ-15 score

Effect	Cohen's d effect size	Estimate	95% CI	t-value	p-value
Telephone-facilitated cCBT vs. minimally supported cCBT (month 4)	0.121	-0.5088	-1.5701 to 0.5526	0.94	0.3460
Telephone-facilitated cCBT vs. minimally supported cCBT (month 12)	0.300	-1.2410	-2.2692 to -0.2127	2.38	0.0182
Telephone-facilitated cCBT vs. minimally supported cCBT (over all assessments)		-1.1099	-1.7521 to 0.0024	1.96	0.0506
Month 4 vs. month 12 (over all treatments)		0.3211	-0.2463 to 0.8884	1.11	0.2661

European Quality of Life-5 Dimensions

The EQ-5D is summarised descriptively at each time point showing the number and percentage of participants with each type of response (Tables 22–26).

TABLE 22 European Quality of Life-5 Dimensions mobility at each time point

Time point	Trial arm		Total (N = 369), n %
	Minimally supported cCBT (N = 182) n %	Telephone-facilitated cCBT (N = 187) n %	
Baseline			
I have no problems in walking about	162 (89.5)	151 (80.7)	313 (85.1)
I have some problems in walking about	19 (10.5)	36 (19.3)	55 (14.9)
I am confined to bed	0 (0.0)	0 (0.0)	0 (0.0)
Month 4			
I have no problems in walking about	98 (83.8)	103 (80.5)	201 (82.0)
I have some problems in walking about	19 (16.2)	25 (19.5)	44 (18.0)
I am confined to bed	0 (0.0)	0 (0.0)	0 (0.0)
Month 12			
I have no problems in walking about	101 (82.1)	108 (82.4)	209 (82.3)
I have some problems in walking about	22 (17.9)	23 (17.6)	45 (17.7)
I am confined to bed	0 (0.0)	0 (0.0)	0 (0.0)

TABLE 23 European Quality of Life-5 Dimensions self-care at each time point

Time point	Trial arm		Total (N = 369), n %
	Minimally supported cCBT (N = 182) n %	Telephone-facilitated cCBT (N = 187) n %	
Baseline			
I have no problems with self-care	171 (94.5)	173 (92.5)	344 (93.5)
I have some problems with self-care	10 (5.5)	14 (7.5)	24 (6.5)
I am unable to wash or dress myself	0 (0.0)	0 (0.0)	0 (0.0)
Month 4			
I have no problems with self-care	107 (91.5)	121 (94.5)	228 (93.1)
I have some problems with self-care	10 (8.5)	7 (5.5)	17 (6.9)
I am unable to wash or dress myself	0 (0.0)	0 (0.0)	0 (0.0)
Month 12			
I have no problems with self-care	116 (94.3)	123 (93.9)	239 (94.1)
I have some problems with self-care	7 (5.7)	8 (6.1)	15 (5.9)
I am unable to wash or dress myself	0 (0.0)	0 (0.0)	0 (0.0)

TABLE 24 European Quality of Life-5 Dimensions usual activities at each time point

Time point	Trial arm		Total (N = 369), n %
	Minimally supported cCBT (N = 182) n %	Telephone-facilitated cCBT (N = 187) n %	
Baseline			
I have no problems with performing my usual activities	84 (46.4)	70 (37.4)	154 (41.8)
I have some problems with performing my usual activities	89 (49.2)	106 (56.7)	195 (53.0)
I am unable to perform my usual activities	8 (4.4)	11 (5.9)	19 (5.2)
Month 4			
I have no problems with performing my usual activities	68 (58.1)	76 (59.4)	144 (58.8)
I have some problems with performing my usual activities	46 (39.3)	47 (36.7)	93 (38.0)
I am unable to perform my usual activities	3 (2.6)	5 (3.9)	8 (3.3)
Month 12			
I have no problems with performing my usual activities	78 (63.4)	79 (60.3)	157 (61.8)
I have some problems with performing my usual activities	43 (35.0)	47 (35.9)	90 (35.4)
I am unable to perform my usual activities	2 (1.6)	5 (3.8)	7 (2.8)

TABLE 25 European Quality of Life-5 Dimensions pain/discomfort at each time point

Time point	Trial arm		Total (N = 369), n %
	Minimally supported cCBT (N = 182) n %	Telephone-facilitated cCBT (N = 187) n %	
Baseline			
I have no pain or discomfort	84 (46.4)	84 (44.9)	168 (45.7)
I have moderate pain or discomfort	87 (48.1)	88 (47.1)	175 (47.6)
I have extreme pain or discomfort	10 (5.5)	15 (8.0)	25 (6.8)
Month 4			
I have no pain or discomfort	56 (47.9)	62 (48.4)	118 (48.2)
I have moderate pain or discomfort	57 (48.7)	60 (46.9)	117 (47.8)
I have extreme pain or discomfort	4 (3.4)	6 (4.7)	10 (4.1)
Month 12			
I have no pain or discomfort	58 (47.2)	67 (51.1)	125 (49.2)
I have moderate pain or discomfort	60 (48.8)	56 (42.7)	116 (45.7)
I have extreme pain or discomfort	5 (4.1)	8 (6.1)	13 (5.1)

TABLE 26 European Quality of Life-5 Dimensions anxiety/depression at each time point

Time point	Trial arm		Total (N = 369), n %
	Minimally supported cCBT (N = 182) n %	Telephone-facilitated cCBT (N = 187) n %	
Baseline			
I am not anxious or depressed	17 (9.4)	9 (4.8)	26 (7.1)
I am moderately anxious or depressed	116 (64.1)	131 (70.1)	247 (67.1)
I am extremely anxious or depressed	48 (26.5)	47 (25.1)	95 (25.8)
Month 4			
I am not anxious or depressed	27 (22.9)	38 (29.7)	65 (26.4)
I am moderately anxious or depressed	78 (66.1)	74 (57.8)	152 (61.8)
I am extremely anxious or depressed	13 (11.0)	16 (12.5)	29 (11.8)
Month 12			
I am not anxious or depressed	35 (28.5)	57 (43.5)	92 (36.2)
I am moderately anxious or depressed	72 (58.5)	61 (46.6)	133 (52.4)
I am extremely anxious or depressed	16 (13.0)	13 (9.9)	29 (11.4)

Computerised cognitive behaviour therapy usage

MoodGYM modules were reported as 25%, 50%, 75% or 100% complete. The percentage of participants in each intervention group who completed all or part of each module is shown in *Table 27*. The telephone-facilitation programme has increased completion rates for each module (*Figure 7*).

Medication to help with depression use

Participants were asked whether or not they were taking medication to help with depression. This included over-the-counter and prescribed medication. Their responses are reported in *Table 28*.

Early participants in the trial were not asked about current medication; data collection started at participant 1151, so numbers at baseline are smaller. The proportions of participants currently taking medication for depression were similar between the two groups at baseline.

Adverse events

There were a total of 10 serious adverse events (*Table 29*), none of which was thought to be related to the trial. All adverse events were reviewed by the Trial Steering Committee and the Data Monitoring and Ethics Committee.

TABLE 27 MoodGYM usage data

Proportion of module completed	Module 1 (%)		Module 2 (%)		Module 3 (%)		Module 4 (%)		Module 5 (%)	
	Minimally supported cCBT	Telephone-facilitated cCBT	Minimally supported cCBT	Telephone-facilitated cCBT	Minimally supported cCBT	Telephone-facilitated cCBT	Minimally supported cCBT	Telephone-facilitated cCBT	Minimally supported cCBT	Telephone-facilitated cCBT
Logged on but did not complete 25%			7.1	5.4	6	8.1	1.1	3.2	1.6	1.1
25% complete	1.6	2.2	2.2	3.8	2.7	2.7				0.5
50% complete	1.6	2.2	3.8	3.8	0.5	4.3	0.5	1.6		
75% complete	2.2	4.8	0.5	3.8	0.5	1.1			0.5	
100% complete	45.1	64.5	29.1	46.2	17.6	28.5	14.3	21.5	10.4	19.4




FIGURE 7 MoodGYM usage session by session.

TABLE 28 Self-reported antidepressant medication use

Time point	Trial arm		Total, n (%)
	Minimally supported cCBT, n (%)	Telephone-facilitated cCBT, n (%)	
Baseline	N= 107	N= 111	N= 218
Yes	71 (66.0)	74 (66.7)	145 (66.5)
No	36 (33.6)	37 (33.3)	73 (33.5)
Month 4	N= 128	N= 141	N= 269
Yes	84 (65.6)	85 (60.3)	169 (62.8)
No	44 (34.4)	56 (39.7)	100 (37.2)
Month 12	N= 132	N= 142	N= 274
Yes	70 (53.0)	68 (47.9)	138 (50.4)
No	62 (47.0)	74 (52.1)	136 (49.6)

TABLE 29 Serious adverse events

Serious adverse events	Trial arm		Total
	Minimally supported cCBT	Telephone-facilitated cCBT	
Number of events	4	6	10
Number unrelated to the trial	4	6	10
Reason for designation			
Hospitalisation	1	2	3
Life-threatening	2	1	3
Death	0	1	1
Resulting in disability or incapacity	1	2	3

Chapter 5 Economic evaluation results

Health-care resource use

Table 30 reports the descriptive statistics of health-care resource use by resource category during the trial follow-up.

Full resource-use data were available for all participants at baseline, and this decreased during follow-up to 67% at 4 months and 69% at 12 months, with complete data across the trial period available for 58.1% of participants from minimally supported cCBT ($n = 98$) and 59.4% from telephone-facilitated cCBT ($n = 111$).

TABLE 30 Resource use from baseline to 12 months of follow-up in available case data set

Health care	Unit	Trial arm					
		Minimally supported cCBT ($n = 98$)			Telephone-facilitated cCBT ($n = 111$)		
		Mean (SD)	Median (IQR)	Use (%)	Mean (SD)	Median (IQR)	Use (%)
Community care							
GP	Visit	7.39 (6.43)	5.33 (10)	98.98	6.67 (4.8)	5.33 (10)	92.2
GP home visit	Visit	0.01 (0.67)	0 (0)	1.02	0.02 (0.15)	0 (0)	2.7
Nurse	Visit	1.02 (1.52)	0 (1.33)	48.98	1.44 (2.58)	0.67 (2)	52.25
Other primary care	Visit	0.39 (1.9)	0 (0)	8.16	2.08 (19.77)	0 (0)	5.41
All day based services	Visit	0.41 (2.83)	0 (0)	6.12	0.17 (1.00)	0 (0)	3.6
Counsellor	Visit	1.34 (3.56)	0 (0)	23.47	1.16 (3.27)	0 (0.67)	26.13
Psychiatric nurse	Visit	0.19 (0.90)	0 (0)	7.14	0.50 (3.39)	0 (0)	6.31
Hospital services							
Inpatient							
Mental health related ^a	Bed-days	0 (0)	0 (0)	0.00	0 (0)	0 (0)	0.00
Non-mental health related ^b	Bed-days	0.24 (1.44)	0 (0)	6.12	0.52 (2.15)	0 (0)	12.61
Outpatient							
Psychiatrist	Visit	0.43 (2.36)	0 (0)	7.14	0.03 (0.26)	0 (0)	1.8
Clinical psychology	Visit	0.43 (2.36)	0 (0)	7.14	0.03 (0.26)	0 (0)	1.8
Non-mental health related ^c	Visit	1.95 (3.67)	0.33 (2)	50	1.59 (4.07)	0 (1.33)	44.14

IQR, interquartile range.

a Mental health-related inpatient services included acute psychiatric care wards, psychiatric rehabilitation wards and psychiatric intensive care units.

b Non-mental health-related inpatient services included general medical wards and long-stay wards.

c Non-mental health-related outpatient wards included accident and emergency services and any other outpatient admissions stated.

General practitioners were visited by nearly all participants throughout the trial (95.08%) but were, on average, more frequently attended by those in the minimally supported cCBT group (mean 7.39 visits) than those in the telephone-facilitated cCBT group (mean 6.67 visits). Hospital inpatient services (both mental health and non-mental health related) were used infrequently across each trial arm for both mental health- and non-mental health-related services. Outpatient hospital attendance for non-mental health-related illnesses was common across both minimally supported cCBT (50%) and telephone-facilitated cCBT (44%). Inpatient mental health-related hospital attendances were low across both groups. Results should be interpreted cautiously as these are unadjusted estimates from the available case data set.

Costs

Table 31 reports the mean costs from baseline to 12 months by treatment group. Mean total costs for the 12-month follow-up were £1172 for minimally supported cCBT versus £1763 for telephone-facilitated cCBT. Total costs appeared broadly similar across both trial arms for mental health-related hospital costs, GP costs, primary care costs and medication costs. However, large disparities were seen in non-mental health-related hospital costs when average costs for telephone-facilitated cCBT (£1050.53) were high with large standard errors compared with the average minimally supported cCBT cost (£561.50). These hospital costs appear to be driven by single participants who had higher costs for ongoing treatments not related to depression. The resultant total costs for these individuals could be considered as outliers. The adjusted mean differences and corresponding 95% CIs obtained through regression analysis are reported in *Cost-effectiveness analysis*.

TABLE 31 Summary of costs

Cost category	Trial arm	
	Minimally supported cCBT (<i>n</i> = 182), mean (SE) (£)	Telephone-facilitated cCBT (<i>n</i> = 187), mean (SE) (£)
NHS costs		
Hospital costs (mental health)	109.08 (39.59)	115.21 (39.39)
Hospital costs (non-mental health)	561.50 (153.88)	1050.53 (383.1)
GP costs	381.58 (40.93)	390.62 (44.00)
Other primary care	111.43 (25.18)	158.08 (39.33)
Medication costs	8.52 (0.79)	7.85 (0.93)
Intervention costs		
Telephone support	–	41.19
Baseline costs	508.71 (51.59)	796.49 (131.26)
Total costs	1172.12 (186.53)	1763.48 (438.77)

SE, standard error.

Health-related quality of life

Table 32 summarises the EQ-5D scores at baseline and at each follow-up period, and total QALYs over the 12-month follow-up. On average, patients in the telephone-facilitated cCBT group reported a slightly lower quality of life than the minimally supported cCBT group at baseline and 4 months, but better quality of life at 12 months.

Mean QALYs estimated through the EQ-5D over 12 months were 0.70 for minimally supported cCBT and 0.686 for telephone-facilitated cCBT. As with the individual EQ-5D scores, the overall QALY difference appears small based on the unadjusted means.

Cost-effectiveness analysis

Base-case cost-effectiveness results

Estimates of incremental mean costs and QALYs based on the regression analysis above were used in the cost-effectiveness analysis. Table 33 presents the fully incremental cost-effectiveness estimates and probability that each intervention is cost-effective at a threshold of £20,000 and £30,000 per QALY. Telephone-facilitated cCBT appears less costly (mean cost difference £3.42) and more effective (mean QALY difference 0.0026) than minimally supported cCBT. At a cost-effectiveness threshold of £20,000 and £30,000 per QALY, the probability that telephone-facilitated cCBT is a cost-effective intervention is 0.55.

TABLE 32 European Quality of Life-5 Dimensions summary scores and QALY estimates (mean, standard error)

Time point/outcome	Trial arm	
	Minimally supported cCBT (<i>n</i> = 182)	Telephone-facilitated cCBT (<i>n</i> = 187)
Baseline	0.620 (0.020)	0.590 (0.021)
4-month follow-up	0.720 (0.021)	0.699 (0.024)
12-month follow-up	0.710 (0.020)	0.716 (0.023)
QALYs	0.700 (0.016)	0.686 (0.019)

TABLE 33 Cost-effectiveness analysis summary table: base case

Treatment	Incremental costs ^{a,b}	Incremental QALYs ^{a,c}	ICER	Probability cost-effective £20,000 per QALY	Probability cost-effective £30,000 per QALY
Minimally supported cCBT	0	0	Dominated	0.45	0.46
Telephone-facilitated cCBT	-£3.42	0.0026		0.55	0.55

a Comparing telephone-facilitated cCBT with minimally supported cCBT.

b Adjusted for baseline costs, age, anxiety level, baseline depression severity, depression duration and sex.

c Adjusted for baseline EQ-5D score, age, anxiety level, baseline depression severity, depression duration and sex.

Figure 8 presents the cost-effectiveness acceptability curves for each treatment. The curve indicates the probability that each intervention is the most cost-effective for a range of maximum amounts that the NHS may be willing to pay to gain an additional QALY. The curve illustrates that the probability that telephone-facilitated cCBT is cost-effective initially increases as the amount the NHS is assumed to be willing to pay for additional health gain rises, becoming fairly stable for higher cost-effectiveness thresholds (approximately \geq £15,000 per QALY).

As a sensitivity analysis, an alternative costing scenario was also considered, which included the same cost categories as the base-case analysis with the exception of all non-mental health-related hospital costs. The cost-effectiveness results are reported in Table 34 and Figure 9. In contrast to previous analyses, minimally supported cCBT is no longer dominated by telephone-facilitated cCBT. The ICER for the comparison of telephone-facilitated cCBT versus minimally supported cCBT is £3596 per QALY. Since this is below the lower bound of the currently recommended NICE cost-effectiveness threshold (£20,000 per QALY), minimally supported cCBT remains the cost-effective intervention in this comparison. At a cost-effectiveness threshold of £20,000 per QALY, the probability that telephone-facilitated cCBT is the cost-effective intervention is 0.55. As for the base-case, the probability of cost-effectiveness across thresholds becomes stable at $>$ £15,000 per QALY, with probability of cost-effectiveness for either intervention remaining equal at £20,000 and £30,000 per QALY.




FIGURE 8 Cost-effectiveness acceptability curves: base case.

TABLE 34 Cost-effectiveness analysis summary table: sensitivity analysis excluding non-mental health-related hospital costs


Treatment	Incremental costs ^{a,b,c}	Incremental QALYs ^{a,d}	ICER	Probability cost-effective £20,000 per QALY	Probability cost-effective £30,000 per QALY
Minimally supported cCBT	0	0	–	0.45	0.45
Telephone-facilitated cCBT	£9.37	0.0026043	£3596.62	0.55	0.55

a Comparing telephone-facilitated cCBT to minimally supported cCBT.

b Adjusted for baseline costs, age, anxiety level, baseline depression severity, depression duration and sex.

c Includes primary care (GP and other), and mental health-related hospital and medication costs.

d Adjusted for baseline EQ-5D score, age, anxiety level, baseline depression severity, depression duration and sex.

**FIGURE 9** Cost-effectiveness acceptability curves: sensitivity analysis excluding non-mental health-related hospital costs.

Summary

The within-trial results of the economic analysis suggest that telephone-facilitated cCBT appeared cost-effective compared with the minimally supported cCBT. In the base case, telephone-facilitated cCBT dominated minimally supported cCBT (i.e. lower mean costs and higher QALYs). Although no longer dominant, telephone-facilitated cCBT remained a cost-effective intervention in the sensitivity analyses (i.e. was well within conventional thresholds used to determine value for money in the NHS of £20,000–30,000 per QALY). However, the differences between the groups were relatively minor for both cost and QALY estimates in each of the separate analyses. Although telephone-facilitated cCBT consistently appeared the cost-effective treatment in the base-case and sensitivity analyses, the results from the probabilistic sensitivity analysis revealed high levels of uncertainty.

Chapter 6 Discussion

The REEACT-2 trial is, to our knowledge, the first head-to-head comparison of minimally supported versus telephone-facilitated cCBT in UK primary care. It answers an important question relating to the level of support required for cCBT in clinical practice in order to ensure uptake of the technology and its clinical effectiveness. The REEACT-2 trial results build on an earlier Health Technology Assessment programme-funded trial (REEACT) in which it was found that cCBT was not effective in the form that it was delivered in routine NHS care (i.e. with minimal professional support).¹² The REEACT-2 trial specifically tests the hypothesis that increasing the level of professional support offered alongside cCBT leads to a greater level of engagement with the computer technology and in turn leads to improved outcomes. The need for the REEACT-2 trial was highlighted by the negative results of the REEACT trial and the emergence of indirect evidence from systematic reviews which showed that meta-analyses of professionally supported cCBT demonstrated larger effect sizes than minimally supported cCBT.⁹

Prior to the REEACT and REEACT-2 trials there had been no large-scale pragmatic trials of cCBT products in UK primary care and the REEACT trials were commissioned following an earlier technology appraisal in this area that identified the need for trials conducted independently of product developers.⁶ The cCBT technology evaluated in the REEACT-2 trial (MoodGYM) was recommended in depression guidelines issued by NICE at the time of design of the REEACT-2 trial, and MoodGYM remains a NICE-endorsed treatment at the time of publication of this trial.³⁹

The REEACT-2 trial was unusual in comparison with earlier trial-based evaluations in that it included an extended follow-up to 12 months. Outcomes were measured across a broad range of domains, including psychological well-being and quality-of-life/health state utility. Important aspects of service utilisation were also recorded, and the trial included a concurrent economic evaluation.

The main findings of the REEACT-2 study will now be discussed in relation to (1) trial-based estimates of the clinical effectiveness of telephone facilitation of cCBT and (2) trial-based estimates of cost-effectiveness.

Trial-based estimates of the clinical effectiveness of telephone-facilitated computer-delivered cognitive behaviour therapy

The REEACT-2 trial found that when telephone facilitation was added to cCBT there were statistically significant benefits in the primary outcome of depression symptomatology and severity across the follow-up period, as measured by a commonly used tool for the identification of depression (PHQ-9). The benefit was most evident at 4 months and the magnitude of benefit was 1.9 points on the PHQ-9 scale, which equated to a small to moderate clinical effect size (Cohen's $d = 0.32$).⁴⁰ By 12 months the between-group difference was attenuated and was no longer statistically significant. The odds of no longer being depressed (defined as a PHQ-9 score of < 10) at 4 months were increased twofold in the facilitated cCBT group compared with minimally supported cCBT group (OR 2.05, 95% CI 1.23 to 3.42).

Turning to the range of secondary outcomes that were collected in the REEACT-2 trial, there was evidence of statistically significant effects on the overall (including all time points) mean depression scores and anxiety scores (as measured by the GAD-7; between-group difference 1.1, 95% CI 0.1 to 2.3; $p = 0.037$). For somatoform complaints there was some evidence of a benefit, but the difference was not statistically significant (PHQ-15 between-group difference 1.1, 95% CI 0.0 to 1.8; $p = 0.051$).

When engagement with cCBT was monitored in the trial with reference to computer records, it was found that there was enhanced uptake and use of programmes. Telephone facilitation, therefore, had the anticipated effect of increasing engagement with computer-based technology. Nevertheless, very few participants (only 19%) completed all five treatment sessions. As was found in the REEACT trial, the use of computer sessions was quite low in the minimally supported treatment arm (with only 45% completing the first session) than in the telephone-facilitated group (65%).

In summary, the main finding is therefore that, for the primary outcome of depression severity and symptomatology, there was a clinically and statistically significant additional benefit across a range of psychological outcomes when participants were offered a telephone-facilitated form of computerised therapy in addition to usual GP care. This benefit was also seen in a range of secondary outcomes. Telephone facilitation resulted in additional clinical improvements when compared with minimally supported cCBT. The comparator arm represented an intervention that replicated cCBT as it is currently offered in routine NHS services, and the additional technology of telephone facilitation was therefore effective in improving clinical outcomes.

Summary of trial-based estimates of cost-effectiveness

The within-trial results of the economic analysis suggest that telephone facilitation resulted in increased quality of life (QALYs) and reduced health-care costs (i.e. it was dominant). In a more conservative sensitivity analysis, the scenario changed and telephone-facilitated cCBT was no longer dominant. However, the additional benefit in terms of QALYs was incurred at an acceptable ratio to costs. In the cost-effectiveness analysis, an ICER of £6933 per additional QALY for telephone facilitation was observed. The addition of telephone facilitation was likely to be cost-effective at a £20,000 per QALY threshold.

Although the cost-effectiveness conclusions appear sensitive to the choice costs, the magnitude of the differences between the two groups was relatively minor for both cost and QALY estimates in both the scenarios. Hence, minor differences in the assumptions can lead to different cost-effectiveness interpretations of either dominance or cost-effectiveness, and some caution should be exercised when interpreting these results. However, under no scenario was telephone facilitation cost-ineffective (> £30,000 per QALY) or dominated by minimally supported cCBT.

Discussion of main findings

The clinical results of the REEACT-2 trial are consistent with some increase in benefit that has been observed in systematic reviews of computer-mediated cCBT.⁹ The addition of telephone facilitation based on a manualised support programme enhanced the effectiveness of cCBT. Minimally supported cCBT (such as is used in the NHS at present) was shown in the REEACT trial to be no more effective than usual GP care. In the REEACT-2 trial, a more intensive telephone facilitation was added to cCBT, and this resulted in statistically significant clinical benefit over and above usual GP care. This finding is important for those who deliver or commission psychological services in primary care. cCBT is a commonly advocated first-line low-intensity treatment option in UK primary care and the offer of this treatment without the provision of telephone facilitation is, on average, unlikely to be of benefit to patients. By adding a level of telephone facilitation that is structured and reinforces the content of CBT treatment sessions, engagement with the programme and clinical outcomes are, on average, improved. The magnitude of this benefit was small to moderate, and was broadly in line with other low-intensity psychological interventions for depression that are delivered in primary care. A systematic review and meta-analysis by Cuijpers *et al.*⁴¹ has demonstrated that the magnitude of effect of primary care-based psychological interventions is, on average, small to moderate (pooled effect size, Cohen's $d = 0.31$, 95% CI 0.17 to 0.45) and the results of the REEACT-2 trial are broadly in line with this body of research.⁴¹ In comparison with other estimates of effect size obtained from developer-led trials, the magnitude of effect observed in REEACT-2 is smaller.

It should be noted that REEACT-2 is a pragmatic trial, which recruited in primary care rather than specialist cCBT services and was conducted independently of product developers. We would therefore expect that the effect size would be smaller and more representative of the benefits expected under conditions of routine care.

To date there have been only limited cost-effectiveness data relating to psychological therapies generally and low-intensity therapies specifically.³⁹ In relation to cCBT there are very few economic evaluations, and those that do exist (e.g. Kaltenthaler *et al.*⁶ and Proudfoot *et al.*⁷) have been conducted alongside developer-led trials framed in specialist services and with larger clinical effect sizes than were observed in the REEACT and REEACT-2 trials. The REEACT and REEACT-2 trials represent the largest economic evaluations of cCBT to date, and directly examine the cost-effectiveness of cCBT from the perspective of the UK NHS. The results of the REEACT-2 trial-based economic evaluation indicate that telephone-supported cCBT is either dominant (cost saving and more effective) or cost-effective within an acceptable threshold of willingness to pay. These economic data will be of interest to decision-makers and those charged with the commissioning of services.

An important feature of the REEACT-2 trial is that we evaluated a free-to-use cCBT package that can be accessed by UK NHS patients at no direct cost. There are a number of cCBT products and packages that could be used in the NHS and that could have been trialled within the REEACT-2 trial. The rationale for choosing MoodGYM was threefold. First, there was evidence of effect from developer-led trials,⁸ suggesting that MoodGYM had the potential to be effective in NHS services. Second, we have shown in the REEACT trial that MoodGYM is not inferior to commercially developed cCBT products.¹² Third, the technology can be accessed at no direct cost to patients in the UK NHS and it had received cautious support in earlier technology appraisals.⁶ The results of the REEACT-2 trial are therefore of relevance to decision-makers as investment or commissioning of the use of cCBT will not require purchase of commercially developed products.

There were limitations to the REEACT-2 trial. The first limitation is that we did not obtain a standardised diagnosis of depression at the point of entry to the trial. Instead, we chose a more pragmatic method that judged the presence of symptomatic depression in a more pragmatic way, according to scores on a depression severity scale (the PHQ-9). We also noted that coexisting anxiety and somatoform complaints were common. Although this might be a more heterogeneous population than that seen in efficacy studies, it could be argued that the participants in the REEACT-2 trial were more representative of people with common mental disorders seen in primary care. The level of severity of depression observed with a PHQ-9 cut-off point of ≥ 10 is in line with moderate depression and previous research has shown that this cut-off point is sensitive and specific in identifying people with clinically significant depression. The second limitation is that the level of use of cCBT was quite low and was lower than that observed in developer-led trials. It might be argued that higher levels of uptake and use might have produced larger and more clinically significant effect sizes. However, we have noted that higher levels of uptake have generally been observed in developer-led trials or studies for which there was intensive one-to-one input from a psychological therapist with the therapist present at the time of delivery of the cCBT intervention.⁷ We would argue that the REEACT-2 trial represented an evaluation of a feasible model of cCBT and low-intensity support that might more readily be delivered at scale within NHS primary care psychological therapy services. The third limitation is the greater than planned level of loss to follow-up that was observed in the REEACT-2 trial. We observed that 27% of participants were lost to follow-up at 4 months and 26% of participants were lost to follow-up at 12 months. There was some evidence of differential attrition, with levels of attrition between 3% and 5% higher in the minimally supported cCBT group. The levels of loss to follow-up were, however, broadly in line with other primary care-based studies of psychological interventions (e.g. King *et al.*⁴²).

Conclusion

Computerised CBT forms a core component of stepped psychological care in the UK primary care and other health systems. We have previously found in the REEACT trial that minimally supported cCBT is clinically ineffective and cost-ineffective and confers no additional benefit over usual GP care for depression. In the REEACT-2 trial, a level of telephone-delivered facilitation was added to cCBT and modest but statistically significant improvements were found in the primary outcome of the presence of depression and other psychological symptoms. Telephone-facilitated cCBT was also cost-effective.

Implications for health care

- In this trial for primary care patients with moderate depression, telephone-facilitated cCBT was clinically effective compared with minimally supported cCBT. Current models of care might usefully be re-examined in the light of these findings with due consideration of the level of support that should be offered alongside cCBT.
- Minimally supported cCBT (which is routinely offered in the NHS in many services) is ineffective and our research suggests that outcomes may improve only when there is sufficient staff in place to support this technology with guidance and facilitation by telephone. This can be offered by telephone according to structured delivery manuals, and allows support to be offered at low intensity and higher volume.
- Telephone-facilitated cCBT is likely to be cost saving or cost-effective to the NHS.

Recommendations for research

- The uptake and use of cCBT was not as high as expected. More research is needed to understand the reasons for lower uptake, and more development is needed for cCBT products to further evolve such that they are more acceptable to people with depression. This requires further research and innovation at the human–computer interface.
- People with depression commonly have coexisting anxiety and somatoform complaints. Although some benefits were observed in these symptoms, the cCBT materials did not specifically address these problems. Further research and development is needed to ensure that cCBT products are able to address coexisting common mental disorders within a single-treatment programme.
- cCBT is a form of self-help. It would be useful to know how cCBT compares to other forms of guided self-help because computer-delivered therapy is not acceptable to a significant portion of patients. Large-scale pragmatic trials of treatments such as bibliotherapy or telephone-based psychological interventions are therefore needed.
- There is a need to examine comparative effectiveness and cost-effectiveness of facilitated cCBT and traditional face-to-face therapy in head-to-head trials.
- All effectiveness studies should be framed in primary care and conducted by researchers other than product developers.
- Studies should include measures of absenteeism/presenteeism and be powered to examine explanatory variables.

Acknowledgements

We would especially like to thank the patients from primary care who agreed to be recruited to take part in this trial. Thanks also to members of the Primary Care Research Network, GPs, research nurses, administrative and other staff at participating GP practices, the Mental Health Research Network and the site research teams. In addition, we would like to thank the Trial Steering Committee and Data Monitoring and Ethics Committee members for overseeing the study.

We also thank Gwen Brierley, who was the trial manager at the start of the trial, and who cowrote the trial protocol and Research Ethics Committee applications; Debbie Tallon, Sarah Knowles, Anna Thake and David White who were the trial co-ordinators at the sites; the many researchers, clinical studies officers and research nurses who recruited participants to the study and collected data; the York Trials Unit for providing the randomisation service, for managing the data and conducting the analysis of the clinical data; and the team of TSWs.

We would also like to extend our gratitude to the developers of MoodGYM, in particular to Kylie Bennett and Ada Tam, for providing us with participant log-ins and usage data.

Contributions of authors

Sally Brabyn (Research Fellow) was the trial manager.

Ricardo Araya (Professor of Global Mental Health), **Michael Barkham** (Professor of Clinical Psychology), **Peter Bower** (Professor of Health Services Research), **Cindy Cooper** (Professor of Health Services Research and Clinical Trials), **David Kessler** (Senior lecturer in Primary Care and General Practitioner), **Karina Lovell** (Professor of Mental Health), **Stephen Palmer** (Professor of Health Economics), **David Richards** (Professor of Mental Health Services) and **Simon Gilbody** (Professor of Psychological Medicine and Health Services Research) were applicants and contributed to the original protocol and study design.

Ana Duarte (Research Fellow), **Richard Mattock** (PhD Student) and **Simon Walker** (Research Fellow) conducted the economic analysis.

Sarah Knowles (Research Fellow), **Debbie Tallon** (Trial Manager) and **David White** (Study Co-ordinator) were site trial co-ordinators, and collected and managed data at their sites.

Sally Brabyn and **Karina Lovell** trained and managed the TSWs.

The report writing team consisted of **Sally Brabyn**, **Ana Duarte**, **Elizabeth Littlewood** (Research Fellow), **Richard Mattock**, **Stephen Palmer**, **Jodi Pervin** (Trial Support Officer), **Simon Walker**, **Gillian Worthy** (Statistician) and **Simon Gilbody**.

Stephen Palmer oversaw the design and conduct of the economic analysis.

Gillian Worthy designed and conducted the clinical analysis.

Simon Gilbody was the chief investigator and chaired the Trial Management Group.

Contributions of collaborators

Helen Lester, Nicola Lidbetter, Mark Sculpher and David Torgerson were coapplicants and contributed to the study design. David Torgerson, Helen Lester and Nicola Lidbetter were members of the Trial Management Group.

Trial Steering Committee members

Professor Joe Reilly (Independent Chairperson), Professor of Mental Health, Durham University.

Professor Mike Slade, Professor of Health Services Research, Head of Section for Recovery, Health Service and Population Research Department, Institute of Psychiatry, King's College London.

Professor Shirley Reynolds, Professor of Evidence-Based Psychological Therapies, University of Reading.

Professor Robbie Foy, Professor of Primary Care, Leeds Institute of Health Sciences, University of Leeds.

Dr Lina Gega, Reader in Mental Health, Northumbria University.

Mr Nick Seccombe (service user representative), informatics and governance lead, Self Help Services, Manchester. Anxiety UK, cCBT self-help services.

Data Monitoring and Ethics Committee members

Professor Mike Lucock (Independent Chairperson), Professor of Clinical Psychology, University of Huddersfield, and Associate Director of Research, South West Yorkshire Partnership NHS.

Professor Chris Roberts, Professor in Biostatistics, Centre for Biostatistics, University of Manchester.

Dr Paul Blenkiron, Consultant Psychiatrist and Honorary Senior Clinical Lecturer, Hull-York Medical School.

Publication

Gilbody S, Brabyn S, Lovell K, Kessler D, Devlin T, Smith L, *et al.* REEACT-2: a large scale pragmatic trial of telephone-supported computerised cognitive behaviour therapy. *Br J Psychiatry* 2016; in press.

Data sharing statement

Available data can be obtained from the data management group through the corresponding author.

References

1. World Health Organization. *The World Health Report (2001): Mental Health: New Understanding, New Hope*. Geneva: World Health Organization; 2001.
2. Layard R. The case for psychological treatment centres. *BMJ* 2006;**332**:1030–2. <http://dx.doi.org/10.1136/bmj.332.7548.1030>
3. Roth A, Fonagy P. *What Works for Whom?: A Critical Review of Psychotherapy Research*. New York, NY: Guildford Press; 1996.
4. Department of Health. *A Review of Strategic Policy on NHS Psychotherapy Services in England*. London: The Stationery Office; 1996.
5. Lovell K, Richards D. Multiple Access Points and Levels of Entry (MAPLE): ensuring choice, accessibility and equity for CBT services. *Behav Cogn Psychother* 2000;**28**:379–91.
6. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, *et al*. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. *Health Technol Assess* 2006;**10**(33). <http://dx.doi.org/10.3310/hta10330>
7. Proudfoot J, Goldberg D, Mann A, Everitt B, Marks I, Gray JA. Computerized, interactive, multimedia cognitive-behavioural program for anxiety and depression in general practice. *Psychol Med* 2003;**33**:217–27. <http://dx.doi.org/10.1017/S0033291702007225>
8. Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. *BMJ* 2004;**328**:265. <http://dx.doi.org/10.1136/bmj.37945.566632.EE>
9. Andersson G, Cuijpers P. Internet-based and other computerized psychological treatments for adult depression: a meta-analysis. *Cogn Behav Ther* 2009;**38**:196–205. <http://dx.doi.org/10.1080/16506070903318960>
10. Spek V, Nyklíček I, Smits N, Cuijpers P, Riper H, Keyzer J, *et al*. Internet-based cognitive behavioural therapy for subthreshold depression in people over 50 years old: a randomized controlled clinical trial. *Psychol Med* 2007;**37**:1797–806. <http://dx.doi.org/10.1017/S0033291707000542>
11. Waller R, Gilbody S. Barriers to the uptake of computerized cognitive behavioural therapy: a systematic review of the quantitative and qualitative evidence. *Psychol Med* 2009;**39**:705–12. <http://dx.doi.org/10.1017/S0033291708004224>
12. Littlewood E, Duarte A, Hewitt C, Knowles S, Palmer S, Walker S, *et al*. A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the randomised evaluation of the effectiveness and acceptability of computerised therapy (REACT) trial. *Health Technol Assess* 2015;**19**(101). <http://dx.doi.org/10.3310/hta191010>
13. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;**16**:606–13. <http://dx.doi.org/10.1046/j.1525-1497.2001.016009606.x>
14. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. *Psychiatr Ann* 2002;**32**:509–21. <http://dx.doi.org/10.3928/0048-5713-20020901-06>
15. Hoffman TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, *et al*. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 2014;**348**:g1687. <http://dx.doi.org/10.1136/bmj.g1687>
16. Khan N, Bower P, Rogers A. Guided self-help in primary care mental health. *Br J Psychiatry* 2007;**191**:206–11. <http://dx.doi.org/10.1192/bjp.bp.106.032011>

17. Christensen H, Griffiths KM, Korten A. Web-based cognitive behavior therapy: analysis of site usage and changes in depression and anxiety scores. *J Med Internet Res* 2002;**4**:e3. <http://dx.doi.org/10.2196/jmir.4.1.e3>
18. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;**166**:1092–7. <http://dx.doi.org/10.1001/archinte.166.10.1092>
19. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002;**64**:258–66. <http://dx.doi.org/10.1097/00006842-200203000-00008>
20. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. *Health Policy* 1990;**16**:199–208. [http://dx.doi.org/10.1016/0168-8510\(90\)90421-9](http://dx.doi.org/10.1016/0168-8510(90)90421-9)
21. Knapp M, Beecham J. Costing mental health services. *Psychol Med* 1990;**20**:893–908. <http://dx.doi.org/10.1017/S003329170003659X>
22. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. *Eval Program Plann* 1979;**2**:197–207. [http://dx.doi.org/10.1016/0149-7189\(79\)90094-6](http://dx.doi.org/10.1016/0149-7189(79)90094-6)
23. Maio GR, Esses VM. The need for affect: individual differences in the motivation to approach or avoid emotions. *J Pers* 2001;**69**:583–614. <http://dx.doi.org/10.1111/1467-6494.694156>
24. Bandura A. Guide for Constructing Self-Efficacy Scales. In Pajares F, Urdan T, editors. *Self-Efficacy Beliefs of Adolescents*. Greenwich, CT: Information Age Publishing; 2006. pp. 307–37.
25. Gilbody S, Richards D, Barkham M. Diagnosing depression in primary care using self-completed instruments: UK validation of PHQ-9 and CORE-OM. *Br J Gen Pract* 2007;**57**:650–2.
26. Mann R, Gilbody S, Richards D. Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. *Soc Psychiat Epidemiol* 2009;**44**:569–78. <http://dx.doi.org/10.1007/s00127-008-0463-5>
27. Beecham J, Knapp M. Costing Psychiatric Interventions. In Thornicroft G, editor. *Measuring Mental Health Needs*. London: Gaskell; 2001. pp. 200–24.
28. Joint Formulary Committee. *British National Formulary*. 69 ed. London: BMJ Group and Pharmaceutical Press; 2015.
29. Netten A, Dennett J. *Unit Costs of Health and Social Care 2014*. Canterbury: Personal Social Services Research Unit, University of Kent; 2014.
30. UK National Health System. *NHS Reference Costs 2012–13. National Schedules of Reference Costs: NHS Own Costs 2013*. 2013. URL: www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 (accessed August 2014).
31. Royston P. Multiple imputation of missing values. *Stata J* 2004;**4**:227–41.
32. Torrance GW, Feeny D. Utilities and quality-adjusted life years. *Int J Technol Assess Health Care* 1989;**5**:559–75. <http://dx.doi.org/10.1017/S0266462300008461>
33. Pullenayegum EM, Tarride J-E, Xie F, Goeree R, Gerstein HC, O'Reilly D. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? *Value Health* 2010;**13**:487–94. <http://dx.doi.org/10.1111/j.1524-4733.2010.00695.x>
34. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. *J Health Serv Res Policy* 2004;**9**:197–204. <http://dx.doi.org/10.1258/1355819042250249>
35. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *J Health Econ* 2001;**20**:461–94. [http://dx.doi.org/10.1016/S0167-6296\(01\)00086-8](http://dx.doi.org/10.1016/S0167-6296(01)00086-8)

36. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. *Methods for the Economic Evaluation of Health Care Programmes*. 3rd edn. Oxford: Oxford University Press; 2005.
37. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal*. London: NICE; 2013.
38. Briggs AH, Claxton K, Sculpher MJ. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
39. National Institute for Health and Care Excellence. *Depression in Adults: The Treatment and Management of Depression in Adults. Update – NICE Clinical Guideline 90*. Manchester: National Institute for Health and Care Excellence; 2009.
40. Cohen J. *Statistical Power Analysis for the Behavioural Sciences*. New York, NY: Academic Press; 1988.
41. Cuijpers P, van Straten A, van Schaik A, Andersson G. Psychological treatment of depression in primary care: a meta-analysis. *Br J Gen Pract* 2009;**59**:e51–60. <http://dx.doi.org/10.3399/bjgp09X395139>
42. King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. *Health Technol Assess* 2000;**4**(19).
43. Curtis L. *Unit Costs of Health and Social Care 2013*. Canterbury: Personal Social Services Research Unit, University of Kent; 2013.
44. Curtis L. *Unit Costs of Health and Social Care 2010*. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
45. Joint Formulary Committee. *British National Formulary* (online). London: BMJ Group and Pharmaceutical Press; 2014. URL: www.bnf.org/bnf/index.htm (accessed August 2014).
46. UK National Health System. *NHS Reference Costs 2011–12. National Schedules of Reference Costs: NHS Own Costs 2012*. 2012. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/127115/NSRC01-2011-12.xls (accessed August 2014).

Appendix 1 Sources and details of unit costs

TABLE 35 Sources and details of key unit costs

Health-care costs	Source	Unit	Cost (£)	Extra information
Community care				
<i>GP</i>				
At surgery	PSSRU 2013 ⁴³	Per hour	230.00	
At surgery	PSSRU 2013 ⁴³	Per consultation	44.85	Average appointment = 11.7 minutes
At home	PSSRU 2013 ⁴³	Per hour	292.00	
At home	PSSRU 2013 ⁴³	Per consultation	113.88	Average appointment = 23.4 minutes
Telephone consultation	PSSRU 2013 ⁴³	Per hour	230.00	
Telephone consultation	PSSRU 2013 ⁴³	Per consultation	27.22	Average appointment = 7.2 minutes
<i>Nurse</i>				
At GP surgery	PSSRU 2013 ⁴³	Per hour	40.00	
At GP surgery	PSSRU 2013 ⁴³	Per consultation	10.33	Average appointment = 15.5 minutes
District nurse	PSSRU 2013 ⁴³	Per hour	48.00	
District nurse	PSSRU 2013 ⁴³	Per consultation	12.40	Average appointment = 15.5 minutes
Psychiatric nurse	PSSRU 2013 ⁴³	Per hour	49.00	
Psychiatric nurse	PSSRU 2013 ⁴³	Per consultation	12.66	Average appointment = 15.5 minutes
<i>Other</i>				
Counsellor	PSSRU 2013 ⁴³	Per hour	48.00	
Counsellor	PSSRU 2013 ⁴³	Per consultation	44.00	Average appointment = 55 minutes
Social worker	PSSRU 2013 ⁴³	Per hour	57.00	
Social worker	PSSRU 2013 ⁴³	Per consultation	52.50	Average appointment = 55 minutes
Occupational therapist	PSSRU 2013 ⁴³	Per hour	34.00	
Occupational therapist	PSSRU 2013 ⁴³	Per consultation	17.00	Average appointment = 30 minutes
Home care worker	PSSRU 2013 ⁴³	Per hour	20.00	
Home care worker	PSSRU 2013 ⁴³	Per consultation	10.00	Average appointment = 30 minutes
<i>Community day care costs</i>				
Day care centre	PSSRU 2013 ⁴³	Per session	38.00	Assumes 1 hour per session
Sheltered workshop	PSSRU 2010 ⁴⁴	Per session	8.40	Assumes 1 hour per session, prices uprated from 2010
<i>Medication</i>				
Antidepressants	BNF ⁴⁵	Per item	4.48	Assumes one prescription per month
Anxiolytics and hypnotics	BNF ⁴⁵	Per item	4.28	Assumes one prescription per month
Propranolol	BNF ⁴⁵	Per item	9.15	Assumes one prescription per month
Pregabalin	BNF ⁴⁵	Per item	64.20	Assumes one prescription per month
Antipsychotics	BNF ⁴⁵	Per item	13.25	Assumes one prescription per month

continued

TABLE 35 Sources and details of key unit costs (continued)

Health-care costs	Source	Unit	Cost (£)	Extra information
Hospital inpatient				
<i>Mental health</i>				
Acute psychiatric ward	PSSRU 2010 ⁴⁴	Per bed-day	333.00	Costs uprated from 2010
Psychiatric rehabilitation ward	NHS reference costs 2010 ⁴⁶	Per bed-day	334.01	Activity weighted average of HRGs related to rehabilitation for psychiatric disorders. Costs uprated from 2010
Psychiatric ICU	PSSRU 2010 ⁴⁴	Per bed-day	650.10	Costs uprated from 2010
<i>Non-mental health</i>				
Long-stay ward	NHS reference costs 2013 ³⁰	Per bed-day	915.92	Activity weighted average of all HRGs for all elective/non-elective procedures
General medical ward	NHS reference costs 2013 ³⁰	Per bed-day	915.92	Activity weighted average of all HRGs for all elective/non-elective procedures
Hospital outpatient				
<i>Mental health</i>				
Psychiatrist	NHS reference costs 2013 ³⁰	Per admission	221.00	Activity weighted average of psychiatric outpatient visits
Clinical psychologist	NHS reference costs 2013 ³⁰	Per admission	191.00	Activity weighted average of psychology outpatient visits
<i>Non-mental health</i>				
A&E visit	NHS reference costs 2013 ³⁰	Per admission	117.00	Activity weighted average of all outpatient A&E visits
Visit (excluding A&E)	NHS reference costs 2013 ³⁰	Per admission	108.00	Activity weighted average of all outpatient HRGs, excluding A&E
Day hospital	NHS reference costs 2013 ³⁰	Per admission	108.00	Activity weighted average of all outpatient HRGs
A&E, accident and emergency; BNF, <i>British National Formulary</i> ; HRG, Healthcare Resource Group; ICU, intensive care unit; PSSRU, Personal Social Services Research Unit.				

Appendix 2 Patient information leaflet



Participant Information Sheet

REEACT-2: Computerised Cognitive Behaviour Therapy for Depression

We invite you to take part in a research study

- Before you decide whether to take part, it is important for you to understand why the research is being done and what it will involve.
- Please take the time to read the following information carefully. Discuss it with friends and relatives if you wish. Take time to decide whether or not you wish to take part.
- You are free to decide whether or not to take part in this research. If you choose not to take part, this will not affect the care you get from your GP.
- Ask us if there is anything that is not clear or if you would like more information.
- Thank you for reading this information sheet. If you decide to take part please sign the consent form and post it back to us in the prepaid envelope provided.

Important things you need to know

- We want to find out more about how computerised cognitive behaviour therapy (CBT) may help people suffering from depression.
- We are particularly interested in exploring whether providing telephone support to patients using computerised CBT has an added benefit to their health.
- Everyone involved in the research study will receive access to a computerised CBT programme.
- By asking you to complete some questionnaires before you start the programme and again at 4 months and 12 months after you enter into the study we hope to understand more about what helps.
- You can stop taking part in the study at any time, without giving a reason.

Contents

- 1 Why we are doing this study
- 2 How the study works
- 3 Why am I being asked to take part?
- 4 What will happen to me if I take part?
- 5 How is taking part in the study different from usual GP care?
- 6 Possible benefits and disadvantages of taking part
- 7 More information about taking part
- 8 Contact for further information

How to contact us

If you have any questions about this study please talk to:

<<Local researcher Name>>

<<Address>>

<<Tel>>

Why we are doing this study

What are we studying?

Depression causes misery to many people and is a major health problem in the UK. The majority of people with depression receive care from their GP and never really see a specialist. However, lots of people experiencing depression would also like to receive a “talking treatment” (counselling or psychotherapy).

What therapy are we looking at?

Cognitive Behaviour Therapy (or ‘CBT’ for short) is an effective type of talking treatment that can help people who have depression. At present CBT is not always immediately available in the NHS. Recently, therapists have developed a form of CBT that can be delivered by computer, which might make it easier to access this form of treatment. We call this “computerised CBT”. Computerised CBT is recommended by the National Institute for Clinical Excellence (NICE) for people experiencing depression, but we need more information about how best to support people who are using it.

What do we hope to find out?

At the moment there is some evidence that suggests people who are using computerised CBT may benefit from receiving additional support from a telephone support worker. The telephone support worker is able to help with any technical difficulties relating to the programme and may also help keep people motivated to continue using it.

This study investigates if providing people with weekly telephone support whilst they use computerised CBT leads to an improvement in their symptoms of depression.

2 How the study works

How do we find out whether telephone support helps?

We do this by setting up everyone who takes part in the study with access to a computerised CBT programme. We then randomly allocate people into one of two groups: one group receives weekly telephone support calls and the other group does not.

How is it decided who gets telephone support?

A computer will choose whether you will receive the telephone support calls – this is called ‘randomisation’. This is a bit like rolling a dice to decide whether you receive telephone support or not. It means you have an equal chance of receiving the telephone support or not.

The rest of this leaflet explains how you might be involved in our research study.

3 Why am I being asked to take part?

Your GP is involved in the study and has identified you as suffering from depression. We hope to get 200 people with depression into the study to help us improve treatment.

4 What will happen to me if I take part?

Enrolling you in the study

If you are interested in taking part you will need to complete the enclosed consent form and return this to your local researcher in the prepaid envelope provided. You will then be contacted by the researcher who will check if you are eligible to take part in the study by asking you some brief questions.

At this point you will also have the opportunity to raise with the researcher any questions you might have about the study. You do not have to enter the study unless you feel completely happy with what you are being asked to do.

Collecting information

If you are eligible to take part and you are happy to proceed with the study the researcher will then ask a series of questions relating to your health. The researcher can either ask you these questions over the telephone or we can arrange to meet you in person. These baseline questions will take about half an hour to complete.

Setting you up with computerised CBT

Everyone who takes part in the study will receive access to a computerised CBT programme called

Moodgym. This is available online and you can use it in your own home if you have internet access. If you do not have internet access at home you will be able to talk through with the researcher where else you may be able to use the programme.

The programme is split into 6 sessions with each session taking about one hour to complete. You will be asked to work your way through the programme completing a session about once a week.

After the initial baseline interview the researcher will provide you with a web address, username and password which will allow you access the Moodgym programme. You will then be able to start the computerised CBT straight away. The researcher will also be able to tell you whether you will be in the group that receives telephone support calls or not.

Telephone support

If you are in the telephone support group you will be contacted by one of the telephone support workers who work on the study. The telephone support worker will explain how they may be able to help you with the computerised CBT and will arrange a suitable time to call you on a weekly basis for up to 8 weeks.

It is important that you are aware that the telephone support workers are not trained counsellors. They will provide technical and motivational support to help you benefit from the computer package. They will not be able to offer advice relating to your emotional health.

If you are in the group without telephone support you will not receive regular telephone calls. You

will however be provided with a free-phone helpline number to ring in case of any problems with the computer programme.

Follow up

Four months after you have entered into the study we will contact you again to ask you a further set of questions to see how you are feeling now. We will also do this 12 months after you have entered into the study.

There are four options to choose from as to how you would like to complete the follow up questions for us:

- (1) the researcher can contact you and go through the questions with you over the telephone
- (2) we can provide you with a web address and password where you can answer the questions online
- (3) we can post you paper versions of the questions for you to complete with a prepaid envelope in which you can return them to us
- (4) we can arrange to meet you in person to go through the questions together

You can let the researcher know how you would prefer to do the follow up questions.

5 How is taking part in the study different from usual GP care?

The main difference will be that you will be set up with a computerised CBT programme by your local researcher. The researcher will also want you to complete some questionnaires before you start the programme and at the follow up points

at 4 and 12 months. If you are in the telephone supported group you will also receive weekly telephone calls from the telephone support worker.

Whilst you are taking part in the study you will continue to be looked after by your GP, as normal. You can see your GP as often as you and he/she thinks necessary. No treatment will be withheld from you during the course of this study.

6 Possible benefits and disadvantages of taking part

What are the possible disadvantages and risks of taking part in REEACT-2?

Computerised CBT is a relatively new treatment for depression. At the moment there is still some uncertainty about how effective it is. It may be that you do not find this method of treatment helpful. At any point during the study you can stop using the programme without having to give a reason why. There are no known side effects of computerised CBT.

What are the possible benefits of taking part in REEACT-2?

We hope that you will be helped by receiving the computerised CBT programme, but this cannot be guaranteed.

By participating in this trial you may receive additional support to use the computerised CBT programme than might otherwise be available in your GP practice.

7 More information about taking part

Do I have to take part?

It is up to you to decide whether or not to take part. We will describe the study and go through this information sheet with you. You are free to withdraw at any time, without giving a reason. This would not affect the standard or type of care you receive.

Will I receive any payment for taking part?

Unfortunately we are not able to offer any expenses or payments to patients who participate in the study. However, participants will be sent a goodwill gesture of £5 with the four- and 12-month follow-up questionnaires.

What happens if new information becomes available during the course of the study?

Sometimes during a study, new information becomes available about the treatment being studied. If this happens, the research team will tell you and discuss whether you want to continue in the study. If you decide to stop taking part in the study your usual GP care will continue. If you decide to continue in the study you may be asked to sign an updated consent form. If we think you

should withdraw from the study, we will explain the reasons and arrange for your care to continue.

What happens when the study stops?

Very occasionally a study is stopped early. If this happens, the reasons will be explained to you and arrangements made for your GP care to continue as usual.

What if there is a problem?

If you have a concern about any aspect of this study you should ask to speak to the researcher who will do their best to answer your questions <<insert local tel>>. Alternatively you could speak to the chief investigator Prof. Simon Gilbody (tel: XXXX).

If you remain unhappy and wish to complain formally, the normal NHS complaints process is available to you.

If you are harmed by taking part, or if you are harmed due to someone's negligence, then you may be able to take legal action.

What will happen to information about me collected during the study?

All information will be held securely and in strict confidence. We keep the information we collect about you separate from your personal details and we can only link this information together with a secure code. Only authorised members of the research team will have access to your information.

We will use the information we collect to look at how best to help people using computerised

CBT. We will keep it for 20 years and then destroy it securely. We will destroy all contact information immediately after the end of the study.

Involvement of your GP

We will tell your GP that you are taking part in the study and inform them of your results on the initial screening questions we use to check if you are eligible to take part. No other questionnaire results will be given to your GP. There is space on the consent form for you to confirm that you are aware of this. We will also inform them whether you are receiving the telephone support calls or not.

If we are worried that you are having thoughts about harming yourself, we may need to discuss these with your GP. We will of course discuss this with you.

If you send us a questionnaire through the post or complete a questionnaire online and we are worried that you are having thoughts about harming yourself, we will let your GP know of our concerns.

What will happen to the results of the study?

When the study is completed, the results will be published in a health care journal so health care professionals can see the results. If published, your identity and personal details will be kept confidential. No named information about you will be published in any report about this study. We will also provide you with a summary of our findings from the study.

Who is organising and funding the study?

This trial is organised by the University of York. The funder is the Health Technology Assessment (HTA) programme.

Who has reviewed the study?

This trial has been reviewed an independent group of people, called the Research Ethics Committee, to protect your safety, rights, well being and dignity. The study has been given a favourable opinion by Bradford Research Ethics committee.

8 Contact for further information

If you have any questions regarding the study or how you might be involved further contact information can be found below.

Local researcher

<<name, address, tel, email>>

Chief Investigator

Thank you for taking the time to consider taking part in this study.

react 2

Appendix 3 Regression coefficients used for cost-effectiveness analysis

TABLE 36 Costs

Base_Total_Costs	Coefficient	Standard error	t-value	p-value	95% CI
Telephone-facilitated cCBT	-24.5895	159.8417	-0.15	0.878	-338 to 288.8209
age	0.337438	5.123713	0.07	0.947	-9.71153 to 10.3864
gender	-110.986	216.7175	-0.51	0.611	-548.532 to 326.5595
anxiety_bl	1.205872	18.9265	0.06	0.949	-36.0859 to 38.49764
PHQ-9_S0_M0	63.33961	22.46457	2.82	0.005	19.21393 to 107.4653
Costs_Bl	1.623163	0.406401	3.99	0	0.817154 to 2.429172
Prev_Dep_None	110.5375	189.6738	0.58	0.56	-262.502 to 483.5772
Prev_Dep_Chron	121.0653	240.7702	0.5	0.615	-351.261 to 593.3917
_cons	-498.323	413.9716	-1.2	0.229	-1310.73 to 314.0801

TABLE 37 Quality-adjusted life-years

QALY	Coefficient	Standard error	t-value	p-value	95% CI
Telephone-facilitated cCBT	0.003742	0.018268	0.2	0.838	-0.03226 to 0.039741
age	-0.00097	0.00064	-1.51	0.133	-0.00224 to 0.000302
gender	0.029349	0.020611	1.42	0.16	-0.01198 to 0.070674
anxiety_bl	-0.00286	0.002206	-1.29	0.197	-0.0072 to 0.001489
PHQ-9_S0_M0	-0.00376	0.002506	-1.5	0.135	-0.00871 to 0.001187
eq5d0	0.488292	0.050897	9.59	0	0.385847 to 0.590738
Prev_Dep_None	0.016942	0.01959	0.86	0.389	-0.02192 to 0.055807
Prev_Dep_Chron	-0.08336	0.023284	-3.58	0	-0.12925 to -0.03747
_cons	0.531626	0.067896	7.83	0	0.397444 to 0.665807

A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and depth.

EME
HS&DR
HTA
PGfAR
PHR

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

Published by the NIHR Journals Library